What Is Skinny Fat? – How to Tell If You’re Metabolically Obese – GoodHousekeeping.com

The notion that weight determines your health is seriously disturbed. As a Registered Dietitian, I know firsthand that calculations like body mass index (BMI) are completely outdated and are a poor measure of health since they only look at weight and height. Looking beyond weight is important to understand what is going on inside your body. Just because you have a normal BMI doesn't necessarily mean you are healthy: enter the term "skinny fat."

The term first gained traction after a piece in Time Magazine profiled individuals who had "normal weight" but had some major underlying health issues. Medically described as metabolically obese normal weight, this refers to people who may have a normal weight or BMI but have risks for health problems in the same way as an outwardly obese person would. Although we don't like the term "skinny fat" as it is super shame-y, it is commonly used describe a serious health issue.

Does your diet primarily consist of excessive sugar, salt, and processed foods? Was the last time you visited a gym back in freshman year of college? Poor diet and lack of exercise, as well as a sedentary lifestyle, can lead to metabolic obesity. Most of us have a decent idea of whether or not we eat a balanced diet and stay active on a consistent basis.

Some more clinical indicators of being metabolically obese that you can discuss with your doctor include:

Diet, exercise, and lifestyle factors all play a huge part in maintaining good health and promoting longevity. Even if you have a normal BMI, high cholesterol and elevated blood sugar can put you at increased risk of heart disease and diabetes. Research has shown that poor diet and lack of exercise are also two key factors that can increase a persons risk of developing cancer.

A big danger for individuals who are metabolically obese is excess visceral fat. While subcutaneous fat (also known as "belly fat") is the layer of fat that sits directly under the skin and can be easy to see, visceral fat lies deeper and surrounds the internal organs. Visceral fat has been strongly linked to metabolic disease and insulin resistance, even for individuals with a BMI within the normal range. You may have heard of the apples and pears scenario that mimics body composition: pears tend to store fat in their lower extremities such as the hips and thighs, whereas apples tend to store fat in the belly. Individuals with an apple shape that store fat in the belly tend to have more visceral fat. Your waist circumference can give you a clearer picture: men should have a waist circumference of less than 40 inches and women should have a waist circumference of less than 35 inches. Cortisol, which is the stress hormone, can also increase how much visceral fat your body stores.

Stay hydrated: Did you know that up to 60% of the human adult body is made up of water? If there is one thing you can do for your health, its to start committing to your hydration. Try lining up your water bottles on your desk so you can see how much you need to drink by the end of the day. When you have a goal and can visualize it, meeting your hydration needs may be easier. You can even fill up a pitcher and keep it in your fridge as a reminder that it must be finished by days end.

Focus on fiber: Fibrous foods like fruits, vegetables, and whole grains are loaded with vitamins and minerals. Plus, fiber can help lower cholesterol levels and also control blood sugar. Fruits and vegetables also are full of water and can help you meet your hydration goal without having to down another water bottle.

Get moving: How are you spending the majority of your day? Are you sitting at a desk or laying on the couch practically 24/7? A study published in 2019 by the European Society of Cardiology found that 20 years of a sedentary lifestyle is associated with a two times risk of premature death. Regular aerobic exercise can also reduce the amount of visceral fat in your body. Consider getting a standing desk at work or just making an effort to get up and move more throughout the day.

Commit to your sleep: Ongoing sleep deficiency is linked to increased risk for several chronic diseases, including heart disease and diabetes. Commit to going to bed an hour earlier and avoid skimping on sleep. Plus, the extra rest may give you more energy to workout the next day.

Excerpt from:
What Is Skinny Fat? - How to Tell If You're Metabolically Obese - GoodHousekeeping.com

The importance of educating scientists – University Affairs

Academic mentorship is a very important part of the education and training of scientists, but it comes with its own set of unique challenges.

The following is the third installment in a five-part series on the core issues facing academic science today that will comprise the foundation of our first book, targeted for publication later this year.

Scientists set a very high bar and facts are actually quite rare. Rather, we consider answers to be accepted if there is a lot of data generated by a lot of different scientists using a lot of different tools that arrive at the same answer; generally accepted, but likely to be refined when there is less data generated by fewer scientists using a limited set of tools to arrive at close but not identical answers; or still uncertain and very likely to change when there is very little data generated by one or a handful of scientists, using a single or very limited set of tools to arrive at a possible answer where there wasnt one before. Over time, scientists strive to reduce uncertainty and eventually arrive at generally accepted answers. It is actually very rare that scientists are so confident in the quality and reproducibility of a particular answer that they would brand it a fact.

As you can imagine, this process takes time and regularly requires generations of scientists to arrive at robust conclusions, making training and mentorship incredibly important to ensure the passage of information and techniques down through the generations. New scientists (students or trainees) train under more experienced scientists (professors or principal investigators) to learn how to perform scientific research. Historically, as the role of advisor or mentor at academic institutions became more commonplace within academic institutions, graduate programs were created to normalize and govern the practice of scientific training, and graduate degrees were created to award and recognize students who had achieved a sufficient level of research independence. This academic mentorship soon became the bedrock of education and training, but it is accompanied by a substantial power dynamic between two people that is vulnerable to disagreement, conflict, and abuse. Over the years, academic institutions have tried to establish rules and regulations to avoid the latter while retaining the benefits of mentorship, although what constitutes good and bad in these relationships has evolved considerably as well.

The goal of all of this wrangling about how we educate and train scientists is to facilitate a greater understanding of the natural world, because this enables societal progress. Discoveries like the wheel, paper, electricity, or antibiotics have created tremendous social value by enabling transportation, communication, energy, and healthcare. These advances have shaped society and improved our quality of life and longevity. Indeed, the very recent application of the scientific method to healthcare has significantly extended the average human lifespan from about 45 years through all of human history and up until the 1900s, to roughly 78 years today (and growing!). That is a three-decade increase in ~100 years, and we continue to gain about one year of life for every six years of basic research investment.

However, scientific discovery is not cheap. How we shoulder this cost will be the focus of our next post.

Original post:
The importance of educating scientists - University Affairs

Human emotions must adapt to thrive in the machine age – TNW

Did you know TNW Conference has a track fully dedicated to bringing the biggest names in tech to showcase inspiring talks from those driving the future of technology this year?Tim Leberecht, who authored this piece, is one of the speakers.Check out the full Impact program here.

If there is pain, nurse it, and if there is a flame, dont snuff it out, dont be brutal with it. Withdrawal can be a terrible thing when it keeps us awake at night, and watching others forget us sooner than wed want to be forgotten is no better. We rip out so much of ourselves to be cured of things faster than we should that we go bankrupt by the age of 30 and have less to offer each time we start with someone new. But to feel nothing so as not to feel anything what a waste!

These are the words of theclosing monologue of the movieCall Me By Your Name(based on the namesake book by Andre Aciman); the monologue of the father, Mr. Perlman, who assures his son Ellio of the inconceivable magnitude of emotions, insisting that even the most conflicted ones are better than none.

These lines could not be more timely. We have begun to realize that feeling more not only makes for richer lives but is also the best antidote to a world of self-optimization and efficiency, in other worlds, a world of machines.

At the World Economic Forum in Davos this year, Alibaba co-founder and executive chairmanJack Mamade the case for investing in our emotional capacities and even proposed a love quotient. Management thinkers believe that socio-emotional skills are going to be a key asset in tomorrows marketplace, simply because tasks requiring operational excellence and efficiency are likely to be performed much more effectively by AI and robots. Emotions, however, remain a human bastion. Our very weakness is our strength.

In a 2016survey, the World Economic Forum ranked socio-emotional skills as increasingly critical for future career success. Business schools are adjusting their curricula to include them, and private educational institutions such asThe School of Lifehave made it their mission to teach them.

Read: [Humility, trust, and empathy: The skills needed to work with robots]

And yet, despite our most ambitious efforts to demystify them, emotions remain utterly mysterious and elusive. They are better felt than explained, better portrayed often through works of arts than analyzed. We dont understand them unless we feel them, and feeling them, of course, is the very blind spot that may prevent us from ever objectively understanding them.

There even appears to be some confusion as to what counts as human emotion and what does not, and which of our emotions are distinctive. For a considerable period of time, common wisdom held that there is a base set of six classic emotions: happy, surprised, afraid, disgusted, angry, and sad. But in 2014, a study by theInstitute of Neuroscience and Psychology at the University of Glasgowclaimed there are only four basic emotions happy, sad, afraid/surprised, and angry/disgusted. Ah, wouldnt life be easy and yet oh-so-boring if that were the case!?

However, in 2017, a new study by theProceedings of National Academy of Sciencessuggested that there are as many as 27 different categories of emotions, and that they in fact occur along a gradient and are not sharply distinguishable or mutually exclusive. This new set of emotions ranges from admiration, adoration, awe, and surprising outliers such as aesthetic appreciation, to envy, excitement, horror, and empathetic pain to equally unexpected contenders such as nostalgia, romance, or triumph.

Looking at this comprehensive list, a few emotions stand out. One wonders whether romance is an emotion or a feeling, an interpretation of an emotion, or simply a way to relate to the world. Similarly, the omission of loneliness is glaring, although in this case, too, one could argue that it is a feeling, not an emotion. Per neuroscientistDr. Sarah McKays definition, feelings aremental experiences of body states, which arise as the brain interprets emotions, themselves physical states arising from the bodys responses to external stimuli. Yet the line between the two remains blurry.

Moreover, some emotions may not have been listed because they areculturally unique, e.g.Schadenfreude, the very German joy over another persons mishap or misfortune. Or these Bantu, Taglog, and Dutch terms:mbuki-mvuki the irresistible urge to shuck off your clothes as you dance kilig the fluttering feeling as you talk to someone to whom you are attracted oruitwaaien the refreshing effects of taking a walk in the wind. Others that were included in the list such as triumphappear to be a temporary sign of our times more than a fixed emotion: in our winner-takes-all societies, winning is arguably the one emotion that is putting all the others in second place. The winner feels it all.

How will digital technology, specifically AI and robotics, affect our emotions?

Researchers have long studied our emotional relationship to machines. Numerousstudieshave proven that we quickly form emotional attachments to robots, and it might indeed be worthwhile exploring which social skills we need in order to collaborate with them.

So-called Artificial Emotional Intelligence (AEI), advanced by firms such asAffectiva,Emotient(acquired by Apple), andEmotion Research Lab, now seeks to analyze our emotions by scanning our facial expressions and body language. From studyingMark Zuckerbergs behavior during the congressional hearingsto the use for candidate assessments in job interviews (HireVue), AEI, like any technology, can be used for benevolent and malicious purposes, from boosting our emotional intelligence to manipulating and emotion-engineering us as citizens and consumers, from helping autistic children recognize their emotions (see, for example, theKaspar project) topenalizing us at the workplace for not being happy.

Empathetic robots occur at the timely convergence of two trends: empathy and AI. As we fear the loss of civility and with xenophobia, racism, and nationalism on the rise in many liberal societies, empathy has become a hot topic, and initiatives to muster it range from podcasts with those who are not like us or even bully us (e.g.Conversations with People Who Hate Me) toMITs Deep Empathyinitiative orGoogles Empathy Lab, to using VR and other immersive technologies as the great empathy machines.

At this yearsConsumer Electronics Showin Las Vegas, several robots were exhibited that can apply empathy and emotional intelligence toward their human user, e.g. the social robot Buddy; the table-tennis playing Forpheus that can read its opponents body language to anticipate their moves; or Pepper, which is capable of interpreting a smile, a frown, your tone of voice, as well as the lexical field you use and non-verbal language such as the angle of your head, according to its manufacturer, SoftBank. InJapan, a society with an aging population, empathetic robots like Paro, applied in elderly care, are becoming a mainstream phenomenon.

Analyst firmGartnerrecently predicted that by 2022 smart machines will understand our emotions better than our close friends and relatives, which of course is an outrageous claim, as the ethnographerJonathan Cookhas pointed out: The more certain research firms claim to be in their ability to measure emotion with quantitative precision, the more incompetent they are likely to actually be at accomplishing the task because they have lost touch with what emotion actually is, he writes.

And yet, the question remains: If robots become better at reading and responding to our human emotions, could technological advances in AI and robotics lead to the emergence of new emotions that were not only previously unmeasured, unnamed, and unidentified, but also un-felt?

You could argue that all possible human emotions have always been present and that we just lacked the words to describe them and only over time simply refined our understanding of them. But there are good arguments for accepting the notion of a history of emotions, the belief that emotions, like our bodies and cognitive abilities, have evolved over time as well, in response to everchanging environments and social stimuli.

Piotr Winkielman and Kent Berridge, psychologists at the UC San Diego and the University of Michigan, conducted an experiment in 2014 in which they showed participants sad and happy faces in such fast order that these had no conscious awareness of seeing any faces at all. When participants were asked afterward to drink a new lemon-lime beverage, those who had subliminally been exposed to the happy faces rated the drink better and also drank more of it than the others. The researchers took this as evidence to suggest the existence of unconscious emotions: feelings we have without actually feeling them. Evolutionarily speaking, the ability to have conscious feelings is probably a late achievement, they concluded. In other words, asentimental education, the education of our hearts, may indeed have been an accomplishment of civilization, a blessing and curse of modern man alike.

Aside from our consciousness of emotions, evolution may have caused new emotions to form. Take envy, and specifically status envy, as a more recent phenomenon, as a product of the industrial revolution and growing consumerism in developed countries. Envy necessitates a materialistic culture. Envy, if you will, is the refined, commoditized version of jealousy. It describes the disappointment and humiliated self that doesnt possess or receive what another one does, a self that finds itself excluded from the marketplace and not able to participate in the transaction.

The natural companion to envy in todays experience economy isFOMO the Fear-Of- Missing-Out. This fear is about missing out onexperience: it is a preemptive fear of loss as much as it is an envy for anothers, possibly richer and more rewarding experience. Ultimately, FOMO is a fear of dying dying without having lived.

While FOMO is its perverse version, boredom is the realhorror vacui. At first glance, it seems like an increasingly precious good. In fact, boredom might become extinct because of the proliferation of smart phones and other devices that deprive us of any vacant moment in time. However, due to automation and the loss of traditional employment, many of us will face more unstructured time in the future and will need help to combat the numbness of boredom as it engulfs our lives.

At the TED conference this year, science writerJessa Gambleheld a fascinating workshop on awe, an emotion triggered, by say, entering the St. Peters Basilica or experiencing the vastness of a desert.

Gamble referenced Stanford researcherMelanie Ruddwho studied the effects of awe on consumer behavior and claims that after feeling awe we tend to choose experiential goods like a movie over material goods like clothes. She further concludes that it also makes us more willing to volunteer in our communities. It looks like we need not only citizenship classes but also experiences of awe to build more civil societies.It is important though to note that awe empowers and disempowers at once. It makes us bigger and smaller. Gamble pointed out that the smaller self was both a prerequisite and consequence of awe: awe overpowers the self. That is both inspiring and humbling.

This very sentiment is at work in our relationship to AI and robots: we are in awe of them, which means, we are enamored and terrified at the same time. The uncanny valley a term used to describe the creepiness of an AI that is nearly fully artificial nor fully flesh, that is arrested at the blurry border between robotic and human, just humanoid enough to trigger our perception of human derangement will be our constant state for the foreseeable future.

It is this tension, this kind of contradictory feeling, that might serve as a blueprint for the future of emotions. The range of what we feel may increase, and it will be less and less binary. Even our language will have to catch up and come up with neologisms expressing this ambivalence. As always, the Germans are especially skilled at inventing new verbs, just consider Verschlimmbessern (which, loosely translated, means making something significantly worse by trying to make it incrementally better).

On the one hand, we are witnessing a radicalization of our emotions, as they are fleeing to the extreme edges (most of us will nod their heads in response to a book title like Pankaj Mishras The Age of Anger); on the other hand, our emotions are becoming more mixed, more conflicted, with different kinds of emotions overlaying each other.

At the same time, the volatility and complexity of our digital times are popularizing emotional states that are simple and balanced, such as mindfulness or the Japanese concept ofikigaithat is attracting more and more followers in the Western world. The Japanese island of Okinawa, whereikigaihas its origins, is said to be home to the largest population of centenarians in the world, and one of the allures of ikigai is the promise of longevity.Ikigaiis the convergence of four primary elements: What you love (your passion), what the world needs (your mission), what you are good at (your vocation), and what you can get paid for (your profession).

Ikigai is similar to the Western concept of purpose that has emerged as the holy grail of organizational and personal transformation. Whats your purpose? as a brand, company, individual, and even nation is the biggest and yet the smallest question everybody is happy to ask and only rarely really able to answer, despite an army of consultants and agencies devoted to it. It is not an entirely new concept. The American philosopher and civil rights leader Howard W. Thurman put it best: Ask what makes you come alive, and go do it. Because what the world needs is people who have come alive.

Mindfulness, ikigai, or purpose are neither emotions nor feelings they are techniques to help us restore balance as our emotions become more extreme and tools to help us refine how we manage them.

Naturally, emotions, too, are affected by the digitization, the atomization of our lives. In our fast-paced daily interactions, micro-aggressions the subtle humiliation by a cranky waiter can sour our mood as much as moments of micro-attachment the smile of a stranger on the subway can make our day. It appears that were transitioning from one emotional state to another much more quickly (the psychologist Susan David has coined the term emotional agility to pinpoint a new skill we must develop to cope with this phenomenon), that were losing the middle ground, the common thread, as well as the stability and continuity of long-term relationships. Instead, we are satisfying our emotional needs either through the instant kicks of the dopamine economy online, little escapisms (social media, gaming, movies, travel), or big ones: assuming an alternate identity, an avatar, a fluid self.

This virtualization of our selves may ultimately lead to the virtualization of our emotions, too, with us going from experiencing age-old emotions in new virtual environments to experiencing new emotions in digital or at least partly digital interactions, to full-on surrogate emotions, digital placeholders of the real thing: fake intimacy, virtual grief, and so on.

Japanese roboticist Hiroshi Ishiguro, who builds humanoid robots and was recently portrayed in this rivetingWired story,is convinced that human emotions are nothing more than responses to external stimuli. David Levy, in his seminal 2007 book,Love and Sex With Robots, subscribes to this point of view: If a robot behaves as though it has feelings, can we reasonably argue that it does not? He argues that human emotions are no less programmed than those of an AI: We have hormones, we have neurons, and we are wired in a way that creates our emotions. Levy projects that roughly by the year 2050 humans will want robots as friends, sexual partners, and even spouses.

This raises some big questions: Will it matter if our human emotions are increasingly manipulated by smart algorithms or even un-real, or does it suffice that wefeelthem? Have emotions ever been pure and can they? Arguably, weve never had much control over them. Emotions are never fully ours rather, despite our insisting on their private nature, theyre part of the public commons and some sort of open-sourced software. And yet, so much of what we feel we are incapable of sharing. We seem to lack the full code for unlocking it, which causes great frustration and a great desire to overcome it. Perhaps, in the future, hacking our brains may involve hacking our emotions, too. Technology may allow us to (re-)mix our emotions together with those of others, as the ultimate form of deep connection.

What makes us human is our proclivity to fall for the other: somebody who is not us, something beyond our control, greater than ourselves. We cant help but be drawn to persons, objects, or experiences that promise us new emotions, new sensations, new highs and lows, new joy and happiness, but also new heartbreak and suffering.

Although we are calling them by our name (Alexa, Buddy, Sophia, Kaspar, Samantha, Erica.), as a mirror of ourselves, the AI bots remain elusive. They are the enigmatic other, the greatest desire of all, the ultimate romance. If they can help us feelmoreand feel new emotions, and if we refine these emotions through more advanced emotional intelligence, with the arts and humanities as our interpreters, then the very machines that are growing adept at analyzing and manipulating how we feel will ensure that we stay a step ahead of them.

This article was originally published by Tim Leberecht, an author, entrepreneur, and the co-founder and co-CEO of The Business Romantic Society, a firm that helps organizations and individuals create transformative visions, stories, and experiences. Leberecht is also the co-founder and curator of the House of Beautiful Business, a global think tank and community with an annual gathering in Lisbon that brings together leaders and changemakers with the mission to humanize business in an age of machines.

Read next: The sustainability of wearables will depend on how we use them

Read more from the original source:
Human emotions must adapt to thrive in the machine age - TNW

Working Monogamy – The Good Men Project

Is true, lasting monogamy a fading institution?

Ive worked with individuals, happily married couples, people on the dating scene, marriages on the rocks, new relationships, poly-amores, and everything in between.

I wouldnt say monogamous relationships are harder or easier to do really well than committed, consensually open relationships.

When Im working with a couple we aim to make their relationship fantastic. With this as the focus they stop thinking of monogamy as an issue either way. Seriously, people who are in a fantastic relationship arent coming to me to discuss their struggles with monogamy. (Or non-monogamy.) Its a non-issue.

That said, here is what we know about monogamy that works:

Working monogamy is monogamy in practice. Its not conceptual. Its not a personality type (as much as one might insist that it is). Monogamy is a relationship state. It means being monogamous to a real live human being, with all of their quirks and gifts and uniqueness.

What this means is, if youre currently in search of your ideal soul-mate, your perfect match on this EarthIf you left a partner who cheated on youIn short, if you are not in a relationshipThen I hate to break it to you: you are not monogamous.

You cant be monogamous without the who that you are monogamous to. What you are instead is what we might call monogamous to monogamy. You are monogamous to an idea. Its simply not the same as being monogamous to someone.

Why? Because it takes a lot to connect with another human being. All the more so, to connect in a way that eclipses all others.

If youre not actually in such a relationship if youre not doing what it takes to connect with someone at that level, grappling with the beautifully messy realities and complexities of human relating Im sorry but you have no claim to monogamy. There are plenty of people out there who are using their laundry list of ideals, monogamy among them, to avoid relationships rather than to get into one.

So get all up in there with someone. Then maybe we can have a meaningful conversation about monogamy.

Working monogamy is organic monogamy. Monogamy that arises spontaneously because the relationship really is that good. Where the thought of being with someone else draws a rather blank stare and a Why?

Organic monogamy is descriptive rather than prescriptive. It requires no effort and draws little attention. It isnt so much chosen or negotiated as discovered.

Monogamy is a convenient label for what youre naturally doing, left to your own devices. Just as the Moon travelling freely through space orbits the Earth. Theres no resisting temptation because there isnt anyone funner, sexier, more attractive, more alluring, or better in bed than the one youre with. There isnt any wandering because there isnt anywhere to go. Any step away is a step down from what youve already got.

I dont advocate monogamy as a principle, that its somehow intrinsically right or good or superior. I believe deeply in monogamy as a way that I have seen can work incredibly well, and I help couples have such a rich, fulfilling relationship that, if theyre choosing monogamy, its because its the natural best option for both of them.

Working monogamy is being monogamous to someone (as opposed to demanding monogamy from someone). It doesnt work that way. Monogamy has everything to do with your behavior and nothing to do with your partners.

Sure, you can extort / demand / insist on your partners monogamy. Perhaps indefinitely. But it will never get you a good relationship if you dont already have one.

I frequent a Facebook group for singles who are all followers of a certain very popular motivational speaker. Recently a woman posted that she met a great guy. She described his many wonderful qualities and how well-suited they were. But he refuses to be monogamous, and she was asking the group for thoughts on what to do. I read through the many responses, most of them some variation of telling her to dump the scoundrel and run as fast as she could, since hell never change. Until we got into a discussion of what she really wanted, what monogamy represented to her:

Exclusivity isnt the same as longevity. Exclusivity isnt the same as depth, or intimacy, or commitment. If your desire is to have a committed, long-lasting, passionate, deep, intimate relationship with someone, the only way is to build that kind of relationship with someone.

As for monogamy itself, the only kind of monogamy we really care about is the organic kind, where the relationship is so fantastic that nothing out there compares to what youve got at home. But that too has to be built. If you demand it, you end up with monogamy without longevity, without passion or intimacy or depth.

So having a monogamous relationship does not consist of finding a monogamous partner. Crappy relationships are the birthplace of all the affairs of the supposedly monogamy-minded. Newlyweds are generally not planning their future affairs.

By the same token, building a fantastic relationship can render open relationship status functionally irrelevant.

But in all my years of coaching/teaching and living, for that matter Ive never seen monogamy, in and of itself, make a crappy relationship fantastic.

Focusing on monogamy as an issue wont improve a relationship, but focusing on improving the relationship can neutralize monogamy as an issue.

Previously Published on Medium

Shutterstock

Read more:
Working Monogamy - The Good Men Project

(2020-2025) Vitamin Market Industry Trends, Growth, Size, Share, Industry Revenue, Future And Business Analysis By Forecast 2025|DSM, Lonza, CSPC…

QY ResearchAnalysts have used latest primary and secondary research methodologies to prepare this highly detailed and accurate report. The research study offers company profiling of leading players operating in theGlobal Vitamin Market 2020. Players profiled in the report are studied on the basis of recent developments, business strategies, financial progress, and main business.

Top Key Players Mentioned in this Report: DSM, Lonza, CSPC Pharmaceutical Group, BASF, Zhejiang Medicine, Shandong Luwei Pharmaceutical, Northeast Pharmaceutical, North China Pharmaceutical, NHU, Jubilant Life Sciences, Vertellus, Brother Enterprises, Adisseo, Zhejiang Garden Biochemical, Kingdomway

Los Angeles, United State, Feb 2020-The report offers a complete research study of the Global Vitamin Market that includes accurate forecasts and analysis at global, regional, and country levels. It provides a comprehensive view of the global Vitamin market and detailed value chain analysis to help players to closely understand important changes in business activities observed across the industry. It also offers a deep segmental analysis of the global Vitamin market where key product and application segments are shed light upon. Readers are provided with actual market figures related to the size of the global Vitamin market in terms of value and volume for the forecast period 2020-2025.

Click Below! For Vitamin Research Report

Major Manufactures Covered in this report:

DSM, Lonza, CSPC Pharmaceutical Group, BASF, Zhejiang Medicine, Shandong Luwei Pharmaceutical, Northeast Pharmaceutical, North China Pharmaceutical, NHU, Jubilant Life Sciences, Vertellus, Brother Enterprises, Adisseo, Zhejiang Garden Biochemical, Kingdomway

Market Segment by Type

Vitamin A, Vitamin B3, Vitamin B5, Vitamin D3, Vitamin E, Vitamin C, Others

Market Segment by Application

Feed Additives, Pharmaceuticals and Cosmetics, Food and Beverage

Global Vitamin Market: Regional Segmentation

For a deeper understanding, the research report includes geographical segmentation of the global Vitamin market. It provides an evaluation of the volatility of the political scenarios and amends likely to be made to the regulatory structures. This assessment gives an accurate analysis of the regional-wise growth of the global Vitamin market.

Regions Covered in the Global Vitamin Market:

The Middle East and Africa (GCC Countries and Egypt) North America (the United States, Mexico, and Canada) South America (Brazil etc.) Europe (Turkey, Germany, Russia UK, Italy, France, etc.) Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

Get Customized Report in your Inbox within 24 [emailprotected]https://www.qyresearch.com/customize-request/form/965258/global-vitamin-industry-depth-survey-report-2019

Key Areas of Focus

Important Questions Answered in this Report:-

Table of Contents

Executive Summary1 Vitamin Market Overview1.1 Product Overview and Scope of Vitamin1.2 Vitamin Segment by Type1.2.1 Global Vitamin Production Growth Rate Comparison by Type (2014-2025)1.2.2 Vitamin A1.2.3 Vitamin B31.2.4 Vitamin B51.2.5 Vitamin D31.2.6 Vitamin E1.2.7 Vitamin C1.2.8 Others1.3 Vitamin Segment by Application1.3.1 Vitamin Consumption Comparison by Application (2014-2025)1.3.2 Feed Additives1.3.3 Pharmaceuticals and Cosmetics1.3.4 Food and Beverage1.3 Global Vitamin Market by Region1.3.1 Global Vitamin Market Size Region1.3.2 North America Status and Prospect (2014-2025)1.3.3 Europe Status and Prospect (2014-2025)1.3.4 China Status and Prospect (2014-2025)1.3.5 Japan Status and Prospect (2014-2025)1.3.6 Southeast Asia Status and Prospect (2014-2025)1.3.7 India Status and Prospect (2014-2025)1.4 Global Vitamin Market Size1.4.1 Global Vitamin Revenue (2014-2025)1.4.2 Global Vitamin Production (2014-2025)

2 Global Vitamin Market Competition by Manufacturers2.1 Global Vitamin Production Market Share by Manufacturers (2014-2019)2.2 Global Vitamin Revenue Share by Manufacturers (2014-2019)2.3 Global Vitamin Average Price by Manufacturers (2014-2019)2.4 Manufacturers Vitamin Production Sites, Area Served, Product Types2.5 Vitamin Market Competitive Situation and Trends2.5.1 Vitamin Market Concentration Rate2.5.2 Vitamin Market Share of Top 3 and Top 5 Manufacturers2.5.3 Mergers & Acquisitions, Expansion

3 Global Vitamin Production Market Share by Regions3.1 Global Vitamin Production Market Share by Regions3.2 Global Vitamin Revenue Market Share by Regions (2014-2019)3.3 Global Vitamin Production, Revenue, Price and Gross Margin (2014-2019)3.4 North America Vitamin Production3.4.1 North America Vitamin Production Growth Rate (2014-2019)3.4.2 North America Vitamin Production, Revenue, Price and Gross Margin (2014-2019)3.5 Europe Vitamin Production3.5.1 Europe Vitamin Production Growth Rate (2014-2019)3.5.2 Europe Vitamin Production, Revenue, Price and Gross Margin (2014-2019)3.6 China Vitamin Production (2014-2019)3.6.1 China Vitamin Production Growth Rate (2014-2019)3.6.2 China Vitamin Production, Revenue, Price and Gross Margin (2014-2019)3.7 Japan Vitamin Production (2014-2019)3.7.1 Japan Vitamin Production Growth Rate (2014-2019)3.7.2 Japan Vitamin Production, Revenue, Price and Gross Margin (2014-2019)

4 Global Vitamin Consumption by Regions4.1 Global Vitamin Consumption by Regions4.2 North America Vitamin Consumption (2014-2019)4.3 Europe Vitamin Consumption (2014-2019)4.4 China Vitamin Consumption (2014-2019)4.5 Japan Vitamin Consumption (2014-2019)

5 Global Vitamin Production, Revenue, Price Trend by Type5.1 Global Vitamin Production Market Share by Type (2014-2019)5.2 Global Vitamin Revenue Market Share by Type (2014-2019)5.3 Global Vitamin Price by Type (2014-2019)5.4 Global Vitamin Production Growth by Type (2014-2019)

6 Global Vitamin Market Analysis by Applications6.1 Global Vitamin Consumption Market Share by Application (2014-2019)6.2 Global Vitamin Consumption Growth Rate by Application (2014-2019)

7 Company Profiles and Key Figures in Vitamin Business7.1 DSM7.1.1 DSM Vitamin Production Sites and Area Served7.1.2 Vitamin Product Introduction, Application and Specification7.1.3 DSM Vitamin Production, Revenue, Price and Gross Margin (2014-2019)7.1.4 Main Business and Markets Served7.2 Lonza7.2.1 Lonza Vitamin Production Sites and Area Served7.2.2 Vitamin Product Introduction, Application and Specification7.2.3 Lonza Vitamin Production, Revenue, Price and Gross Margin (2014-2019)7.2.4 Main Business and Markets Served7.3 CSPC Pharmaceutical Group7.3.1 CSPC Pharmaceutical Group Vitamin Production Sites and Area Served7.3.2 Vitamin Product Introduction, Application and Specification7.3.3 CSPC Pharmaceutical Group Vitamin Production, Revenue, Price and Gross Margin (2014-2019)7.3.4 Main Business and Markets Served7.4 BASF7.4.1 BASF Vitamin Production Sites and Area Served7.4.2 Vitamin Product Introduction, Application and Specification7.4.3 BASF Vitamin Production, Revenue, Price and Gross Margin (2014-2019)7.4.4 Main Business and Markets Served7.5 Zhejiang Medicine7.5.1 Zhejiang Medicine Vitamin Production Sites and Area Served7.5.2 Vitamin Product Introduction, Application and Specification7.5.3 Zhejiang Medicine Vitamin Production, Revenue, Price and Gross Margin (2014-2019)7.5.4 Main Business and Markets Served7.6 Shandong Luwei Pharmaceutical7.6.1 Shandong Luwei Pharmaceutical Vitamin Production Sites and Area Served7.6.2 Vitamin Product Introduction, Application and Specification7.6.3 Shandong Luwei Pharmaceutical Vitamin Production, Revenue, Price and Gross Margin (2014-2019)7.6.4 Main Business and Markets Served7.7 Northeast Pharmaceutical7.7.1 Northeast Pharmaceutical Vitamin Production Sites and Area Served7.7.2 Vitamin Product Introduction, Application and Specification7.7.3 Northeast Pharmaceutical Vitamin Production, Revenue, Price and Gross Margin (2014-2019)7.7.4 Main Business and Markets Served7.8 North China Pharmaceutical7.8.1 North China Pharmaceutical Vitamin Production Sites and Area Served7.8.2 Vitamin Product Introduction, Application and Specification7.8.3 North China Pharmaceutical Vitamin Production, Revenue, Price and Gross Margin (2014-2019)7.8.4 Main Business and Markets Served7.9 NHU7.9.1 NHU Vitamin Production Sites and Area Served7.9.2 Vitamin Product Introduction, Application and Specification7.9.3 NHU Vitamin Production, Revenue, Price and Gross Margin (2014-2019)7.9.4 Main Business and Markets Served7.10 Jubilant Life Sciences7.10.1 Jubilant Life Sciences Vitamin Production Sites and Area Served7.10.2 Vitamin Product Introduction, Application and Specification7.10.3 Jubilant Life Sciences Vitamin Production, Revenue, Price and Gross Margin (2014-2019)7.10.4 Main Business and Markets Served7.11 Vertellus7.12 Brother Enterprises7.13 Adisseo7.14 Zhejiang Garden Biochemical7.15 Kingdomway

8 Vitamin Manufacturing Cost Analysis8.1 Vitamin Key Raw Materials Analysis8.1.1 Key Raw Materials8.1.2 Price Trend of Key Raw Materials8.1.3 Key Suppliers of Raw Materials8.2 Proportion of Manufacturing Cost Structure8.3 Manufacturing Process Analysis of Vitamin8.4 Vitamin Industrial Chain Analysis

9 Marketing Channel, Distributors and Customers9.1 Marketing Channel9.1.1 Direct Marketing9.1.2 Indirect Marketing9.2 Vitamin Distributors List9.3 Vitamin Customers

10 Market Dynamics10.1 Market Trends10.2 Opportunities10.3 Market Drivers10.4 Challenges10.5 Influence Factors

11 Global Vitamin Market Forecast11.1 Global Vitamin Production, Revenue Forecast11.1.1 Global Vitamin Production Growth Rate Forecast (2019-2025)11.1.2 Global Vitamin Revenue and Growth Rate Forecast (2019-2025)11.1.3 Global Vitamin Price and Trend Forecast (2019-2025)11.2 Global Vitamin Production Forecast by Regions (2019-2025)11.2.1 North America Vitamin Production, Revenue Forecast (2019-2025)11.2.2 Europe Vitamin Production, Revenue Forecast (2019-2025)11.2.3 China Vitamin Production, Revenue Forecast (2019-2025)11.2.4 Japan Vitamin Production, Revenue Forecast (2019-2025)11.3 Global Vitamin Consumption Forecast by Regions (2019-2025)11.3.1 North America Vitamin Consumption Forecast (2019-2025)11.3.2 Europe Vitamin Consumption Forecast (2019-2025)11.3.3 China Vitamin Consumption Forecast (2019-2025)11.3.4 Japan Vitamin Consumption Forecast (2019-2025)11.4 Global Vitamin Production, Revenue and Price Forecast by Type (2019-2025)11.5 Global Vitamin Consumption Forecast by Application (2019-2025)

12 Research Findings and Conclusion

13 Methodology and Data Source13.1 Methodology/Research Approach13.1.1 Research Programs/Design13.1.2 Market Size Estimation13.1.3 Market Breakdown and Data Triangulation13.2 Data Source13.2.1 Secondary Sources13.2.2 Primary Sources13.3 Author List13.4 Disclaimer

*Thanks For Reading this Article. you can visit our web site for more Trending Reports.*

About Us:QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from the huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become a brand of quality assurance in the consulting industry.

View post:
(2020-2025) Vitamin Market Industry Trends, Growth, Size, Share, Industry Revenue, Future And Business Analysis By Forecast 2025|DSM, Lonza, CSPC...

Americans say this popular diet is effective and inexpensive – YouGov US

Many Americans aim to eat a healthy diet, and some might be hoping to lose a few pounds. But which diets are Americans sticking to, and which ones are actually helping them lose weight?

A YouGov poll of more than 1,200 US adults finds that a majority of Americans have changed their diet at some point in order to lose weight (56%) or improve their physical health (54%).

Intermittent fasting, a diet where you only eat during certain times of day, is one of the most popular: 24 percent of US adults say theyve tried this diet for weight loss. An equal number say theyve tried the Atkins diet, which emphasizes foods that are low-carb.

About one in five have tried Weight Watchers (21%), the keto diet (19%) and the Mediterranean diet (18%).

But which diets do Americans say have been effective in helping them lose weight?

YouGovs data finds that majorities of people who have used these diets for weight loss find them to be effective.

Almost nine in 10 (87%) people who have tried intermittent fasting to lose weight say that this diet was very effective (50%) or somewhat effective (37%) in helping them lose weight. A similar number of people who have used Weight Watchers (86%) or the keto diet (85%) say these diets were effective for weight loss.

Majorities who have used Atkins (83%), the Mediterranean diet (81%), or vegetarianism (78%) for weight loss also say that these diets were effective in helping them to lose weight.

The diet Americans say is the best weight-loss diet may also be the most affordable one.

Intermittent fasting, which 87 percent of users say was effective for weight loss, is also seen as more inexpensive (80%) than expensive (18%), according to people who have tried it.

That isnt the case for many of the other diets YouGov asked Americans about. Majorities of users are more likely to see Weight Watchers, keto, Atkins and the Mediterranean diet as more expensive rather than inexpensive. Those who have adopted a vegetarian diet for weight loss are close to evenly split: 49 percent say it is expensive, 46 percent say it is inexpensive.

But in spite of the fact that many of these diets seem to be effective according to the people who have tried them, they remain largely unappealing to the American public.

A majority (58%) of US adults say that the vegetarian diet is somewhat or very unappealing. A plurality say the same when asked about the keto diet (47% find it unappealing), Atkins (47%), intermittent fasting (47%), or Weight Watchers (47%).

The only diet of this grouping that was seen as more appealing than unappealing was the Mediterranean diet. Over half (55%) say this diet is somewhat or very appealing; 31 percent say it is unappealing.

See the full survey results and sign up to be a part of the YouGov panel.

Related: One in five Millennials has changed their diet to reduce their impact on the planet

Methodology: Total unweighted sample size was 1,241 US adults, which included 137 who have used the keto diet for weight loss, 165 who have used the Atkins diet for weight loss, 172 who have used intermittent fasting for weight loss, 120 who have used the Mediterranean diet for weight loss, 146 who have used Weight Watchers for weight loss, and 95 who have used vegetarianism for weight loss. The figures have been weighted and are representative of all US adults (ages 18+). Interviews were conducted online between January 3 - 6, 2020.

Image: Getty

More here:
Americans say this popular diet is effective and inexpensive - YouGov US

Balancing health with your culture – The Miami Hurricane

The 2010s saw a dramatic spike in new health trends. Specifically, more people turned to veganism and vegetarianism as a lifestyle. The biggest food prediction for this new decade is a plant-based revolution that will take the mainstream media by storm. Its no secret that eating less meat can be beneficial for your health while also helping the environment. However, with these popular food trends, it can be tricky to also honor ones culture. Cuisine is a major part of every culture and it is challenging to try new things while also staying true to your roots.

Since I was a kid Ive always been interested in plant-based food options and I would constantly drag my mom and sister to the quaint vegan cafes that began popping up throughout Miami. I think its important to try new things, especially when they can improve your health and expand your knowledge on the positive impacts eating the right foods can make. Exploring these vegan or vegetarian food trends is especially difficult when your cultures cuisine is very meat-centric. I come from a Cuban background and one of our main dishes is a bistec de palomilla, or butter-fried beef steak, usually paired with a side of rice and beans. As a person who hasnt had any type of steak in over three years, I can leave people confused.

Youre Cuban but you dont eat meat? is a question I hear a lot, but I think its important to separate heritage and culture from health choices because culture can be honored and celebrated in other ways besides food.

My best friend who is also Cuban can relate to this issue, having been a committed vegetarian for almost four years. In Cuban culture, Christmas Eve, or Noche Buena, is a big deal for us. The designated dish for this celebration is lechon, or pork, but for a vegetarian spending Christmas Eve with a Cuban family, it can be difficult to balance this tradition with personal choices.

I think the best way to navigate these situations is to remember that food is not tied to your identity, and although it may feel like food is the center of your culture, you can still express your heritage through alternate ways, including music, dress, meat-free food options and other customs that dont compromise the health-conscious decisions you want to abide by.

While I havent cut out meat from my diet entirely, I feel that cutting out red meat was the right choice for me and it has helped me feel better physically. I no longer feel sluggish after eating like I used to when I had massive cheeseburgers every other week. Now I opt for a turkey or veggie burger, and when Im really craving meat, Ill order an Impossible Burger, which is entirely plant-based but tastes and even looks like the real deal.

The vegan phenomenon is often criticized because it makes people feel outcasted if they still eat meat, but I think thats the wrong angle to take. I think it all comes down to respecting peoples personal choices, whether that means having meat regularly or leaning towards a more plant-based life. And these choices dont define how strong your pride is for your culture, because it is definitely possible to strike a balance between the traditions of the past and the new ideas of the present.

Nicole Macias is a senior majoring in English.

Read more:
Balancing health with your culture - The Miami Hurricane

Harrison Ford Ditches Meat and Dairy and Says he is Vegetarian – The Beet

Harrison Ford isn't just Indiana Jones or the most famous Wookie-loving pilot in the Galaxy. Now he is adding to his many roles. After playing heroes as lovable as Han Solo, Indie and the original Jack Ryan of the big screen, Ford just yesterday announced that he was giving up meat and dairy "to help the environment."

Speaking about his new diet, Ford said: "I eat vegetables and fish, no dairy, no meat. I just decided I was tired of eating meat and I know it's not really good for the planet, and it's not really good for me." This follows his speech last fallatthe UN Climate Action Summit where he spoke about the environmental crisis and saving the Amazon rainforests.

Always fit, always preternaturally youthful and always on the move, Ford is another "cool guy" who has joined the ranks of plant-lovers. When Arnold Schwartzenegger and James Cameron speak out against meat and dairy, and the benefits of adopting a plant-based diet for their health and performance, guys sit up and listen. There is the usual discussion of "Where do I get my protein?" and "What the heck do I eat?" which are all good questions and The Beet has complete guides to the best sources of plant-based protein and 21 days of ready-to-cook recipes as part of our 21 Day Plant-Based Challenge. But less and less, do you hear the line of resistance that goes something like: Real men eat meat. And Vegetarianism is for girls. Because it's not.

Ford says his athletic body is due to his diet more than hitting the gym, according to a recent interview, and insists he doesn't "work out" like crazy.

Making an appearance on The Ellen DeGeneres Show, he added: "I don't work out like crazy; I just, I work out a bit. I ride bikes and I play tennis and a little bit."

Meanwhile, Harrison has claimed the only people that can save the world are "angry" young people.

The Hollywood icon, now 77, appeared on Tuesday's edition of The Ellen DeGeneres Show, and went into detail about delivering his speech to save the Amazon rain forest last fall at the UN Climate Action Summit.

Asked if he was nervous beforehe gave the speech, the Oscar-nominated actor replied, 'Not until I [got] there - I don't have enough sense to be.'

'I was in this room, I was on a dais ... and everybody else was a head-of-state and I thought, "Oh man they made some big mistake here,"' Ford said. 'But then they let me talk about what I wanted to talk about - which is the environment.' The Daily Mail of London broke the story.

"We've been talking about saving the Amazon for 30 years. We're still talking about it," Ford continued. "The world's largest rain forest, the Amazon is crucial to any climate change solution for its capacity to sequester carbon, for its biodiversity, for its freshwater, for the air we breathe, for our morality. And it is on fire. When a room in your house is on fire, you don't say, 'there is a fire in a room in my house.' You say, 'My house is on fire,' and we only have one house ... They are the young people who, frankly, we have failed - who are angry, who are organized, who are capable of making a difference. The most important thing that we can do for them is to get the hell out of their way."

On a lighter note, Ellen accused Ford of riding an electric-powered bike, a fact he adamantly denied.

Go here to read the rest:
Harrison Ford Ditches Meat and Dairy and Says he is Vegetarian - The Beet

A wider platter – The Indian Express

Written by Nayanjot Lahiri | Updated: February 25, 2020 2:02:33 am A promotional image for Historical Gastronomica. (File) With an impressive variety of meats, fish, and fowl, the cuisine of the Harappan city dwellers would even today be considered a gourmands delight.

Harappan food was rich in all kinds of fleshy delights. Indeed, with an impressive variety of meats, fish and fowl, the cuisine of the Harappan city dwellers would even today be considered a gourmands delight.

Before giving a graphic description of the nourishing non-vegetarian fare that they delighted in consuming, perhaps I should mention how food remains are studied. Within the material culture that has survived, there is the garbage of everyday life found at archaeological sites around the production and consumption of food vast quantities of broken and discarded pottery, chewed and charred animal bones, sundry cereals and seeds of fruits and implements used in producing and processing food. Such artefacts are now studied through scientific techniques that can even indicate whether stone tools were used to cut meat or wild grass, and whether grinding stones mashed mangoes or cereals.

In India, unfortunately, we dont get direct evidence of a meal, that is, of what ancient people consumed at a particular time and day because this comes from the stomachs and the excreta of past people. Neither of these have survived in archaeological contexts here.

Opinion | Harappan meat-eaters, Lutyens vegetarians

Occasionally, a single sample on a site will yield large amounts of material. At the Harappan city of Surkotada, charred lumps of carbonised seeds were discovered from an earthen pot. Two of the charred lumps yielded nearly 600 specimens, an overwhelming majority of which were from wild plants. Only about 7 per cent were identified as being of cereals. The cereals were millets, wild and cultivated, wild grasses, nuts, and weeds. This cannot give clues to the relative importance of different cereals because the sample only reflects a moment in time.

Plant remains from Harappan sites reveal the entire repertoire, from cereals and lentils to fruits and vegetables, and even the spices used. Recognising grains is easy and has been done for nearly a century since the discovery of Mohenjodaro and Harappa because burnt cereals survive rather well and sometimes also leave an imprint on clay. Among vegetables and fruits, it is usually their seeds that are identified. More recently, the archaeologist Arunima Kashyap has recovered and identified at Harappan Farmana (in rural Haryana), starch granules from pots, grinding stones, and teeth, showing the processing, cooking and consumption of mangoes, bananas and garlic. What was left over after the household ate was evidently fed to their animals since the same starch granules were scraped off the teeth from cattle remains found there.

The first thorough investigation of ancient animal remains from an archaeological site anywhere in the Indian subcontinent was done at Mohenjodaro, published in 1931 in the first excavation report of the city. Written by Colonel R B Seymour Sewell and B S Guha, no less than 37 species were identified. There were domesticated and wild animals and included a considerable frequency of humped cattle, pig, and fish. Apparently, gharials and turtles, remains of which in many cases have been burnt, indicate that such animals formed part of the food of that city. Since then, as a 1994 article by P K Thomas and P P Joglekar revealed, there have been some two dozen Harappan sites whose animal remains are reported. Interestingly, cattle bones account for more than 70 per cent of the bones and, in fact, any Harappan site where bones have been found, without exception, has yielded cattle bones. Evidently, while cattle were used for agricultural operations and as draught animals, their meat was vastly enjoyed. Mutton was the other food that was commonly consumed as were pigs.

Animal teeth have also been studied to understand when the victims were killed. At Harappan Oriyo Timbo (in Gujarat), nearly 15,000 animal bones were recovered and annular rings accurately fixed the age and season of death of fauna. The microscopic annuli on a dental substance known as cementum was carefully assessed. What these revealed was that cattle, sheep and goat were slaughtered from March to July. Usually, very young animals were not killed, and slaughtering was most common in cattle samples at 30 months and 18 months in sheep/goat. Mature animals bones were also very common which underlines that adult animals were valued for their productive capacity.

The animals that Harappans kept and consumed is rather well known. What is less known is the range of wild animals enjoyed by them and the fact that these contributed greatly to their diet. Various types of deer and antelopes were hunted, and many varieties of birds, turtles, fish, crabs and molluscs were found as Thomas and Joglekar point out, in the kitchen refuse. We also know that ancient Punjabis at the city of Harappa enjoyed marine catfish.

Among wild animals, from Gujarats Kuntasi and Shikarpur, bones of wild ass with cut marks and evidence of charring underlines that they were hunted for food. Gujarats Harappan sites, as Shibani Boses just published book on Mega Mammals in Ancient India reveals, also show the presence of rhinoceros. It is animals that are normally eaten which find their way into archaeological deposits and that is likely to be the reason why these bones are so commonly found. In the case of Nausharo in Baluchistan, rhino bones were found in a hollow along with trash. What Bose also points out is the consumption of rhino meat in historical India and that texts on Indian medicine like the Caraka Samhita attribute definite health benefits to it.

Some scriptures did frown on or had misgivings about killing and consumption of animals. The Satapatha Brahmana, an ancient Indian religious text that forms part of the Vedic corpus, is full of fine detail about sacrificial ritual, and the eater of meat is said to be eaten in his next birth by the animal killed. Regardless of these occasional scriptural impediments, the general picture is of an ancient populace not just carnivorous but eagerly so.

All this should give pause to modern advocates of vegetarianism who want to make ancient Indians in general and Harappans in particular appear to be like them. Harappans would most certainly have scoffed at such attempts, even as they chomped through chunks of roasted cattle and pig.

The writer is professor of history at Ashoka University

The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines

For all the latest Opinion News, download Indian Express App.

View post:
A wider platter - The Indian Express

Stem cells and the heartthe road ahead – Science Magazine

Heart disease is the primary cause of death worldwide, principally because the heart has minimal ability to regenerate muscle tissue. Myocardial infarction (heart attack) caused by coronary artery disease leads to heart muscle loss and replacement with scar tissue, and the heart's pumping ability is permanently reduced. Breakthroughs in stem cell biology in the 1990s and 2000s led to the hypothesis that heart muscle cells (cardiomyocytes) could be regenerated by transplanting stem cells or their derivatives. It has been 18 years since the first clinical trials of stem cell therapy for heart repair were initiated (1), mostly using adult cells. Although cell therapy is feasible and largely safe, randomized, controlled trials in patients show little consistent benefit from any of the treatments with adult-derived cells (2). In the meantime, pluripotent stem cells have produced bona fide heart muscle regeneration in animal studies and are emerging as leading candidates for human heart regeneration.

In retrospect, the lack of efficacy in these adult cell trials might have been predicted. The most common cell type delivered has been bone marrow mononuclear cells, but other transplanted cell types include bone marrow mesenchymal stromal cells and skeletal muscle myoblasts, and a few studies have used putative progenitors isolated from the adult heart itself. Although each of these adult cell types was originally postulated to differentiate directly into cardiomyocytes, none of them actually do. Indeed, with the exception of skeletal muscle myoblasts, none of these cell types survive more than a few days in the injured heart (see the figure). Unfortunately, the studies using bone marrow and adult resident cardiac progenitor cells were based on a large body of fraudulent work (3), which has led to the retraction of >30 publications. This has left clinical investigators wondering whether their trials should continue, given the lack of scientific foundation and the low but measurable risk of bleeding, stroke, and infection.

Additionally, investigators have struggled to explain the beneficial effects of adult cell therapy in preclinical animal models. Because none of these injected cell types survive and engraft in meaningful numbers or directly generate new myocardium, the mechanism has always been somewhat mysterious. Most research has focused on paracrine-mediated activation of endogenous repair mechanisms or preventing additional death of cardiomyocytes. Multiple protein factors, exosomes (small extracellular vesicles), and microRNAs have been proposed as the paracrine effectors, and an acute immunomodulatory effect has recently been suggested to underlie the benefits of adult cell therapy (4). Regardless, if cell engraftment or survival is not required, the durability of the therapy and need for actual cells versus their paracrine effectors is unclear.

Of particular importance to clinical translation is whether cell therapy is additive to optimal medical therapy. This remains unclear because almost all preclinical studies do not use standard medical treatment for myocardial infarction. Given the uncertainties about efficacy and concerns over the veracity of much of the underlying data, whether agencies should continue funding clinical trials using adult cells to treat heart disease should be assessed. Perhaps it is time for proponents of adult cardiac cell therapy to reconsider the approach.

Pluripotent stem cells (PSCs) include embryonic stem cells (ESCs) and their reprogrammed cousins, induced pluripotent stem cells (iPSCs). In contrast to adult cells, PSCs can divide indefinitely and differentiate into virtually every cell type in the human body, including cardiomyocytes. These remarkable attributes also make ESCs and iPSCs more challenging to control. Through painstaking development, cell expansion and differentiation protocols have advanced such that batches of 1 billion to 10 billion pharmaceutical-grade cardiomyocytes, at >90% purity, can be generated.

Preclinical studies indicate that PSC-cardiomyocytes can remuscularize infarcted regions of the heart (see the figure). The new myocardium persists for at least 3 months (the longest time studied), and physiological studies indicate that it beats in synchrony with host myocardium. The new myocardium results in substantial improvement in cardiac function in multiple animal models, including nonhuman primates (5). Although the mechanism of action is still under study, there is evidence that these cells directly support the heart's pumping function, in addition to providing paracrine factors. These findings are in line with the original hope for stem cell therapyto regenerate lost tissue and restore organ function. Additional effects, such as mechanically buttressing the injured heart wall, may also contribute.

Breakthroughs in cancer immunotherapy have led to the adoption of cell therapies using patient-derived (autologous) T cells that are genetically modified to express chimeric antigen receptors (CARs) that recognize cancer cell antigens. CAR T cells are the first U.S. Food and Drug Administration (FDA)approved, gene-modified cellular pharmaceutical (6). The clinical and commercial success of autologous CAR T cell transplant to treat B cell malignancies has opened doors for other complex cell therapies, including PSC derivatives. There is now a regulatory path to the clinic, private-sector funding is attracted to this field, and clinical investigators in other areas are encouraged to embrace this technology. Indeed, the first transplants of human ESC-derived cardiac progenitors, surgically delivered as a patch onto the heart's surface, have been carried out (7). In the coming years, multiple attempts to use PSC-derived cardiomyocytes to repair the human heart are likely.

What might the first human trials look like? These studies will probably employ an allogeneic (non-self), off-the-shelf, cryopreserved cell product. Although the discovery of iPSCs raised hopes for widespread use of autologous stem cell therapies, the current technology and regulatory requirements likely make this approach too costly for something as common as heart disease, although this could change as technology and regulations evolve. Given that it would take at least 6 months to generate a therapeutic dose of iPSC-derived cardiomyocytes, such cells could only be applied to patients whose infarcts are in the chronic phase where scarring (fibrosis) and ventricular remodeling are complete. Preclinical data indicate that chronic infarcts benefit less from cardiomyocyte transplantation than do those with active wound-healing processes.

Adult cells from bone marrow or the adult heart secrete beneficial paracrine factors but do not engraft in the infarcted heart. Pluripotent stem cells give rise to cardiomyocytes that engraft long term in animal models, beat in synchrony with the heart, and secrete beneficial paracrine factors. Long-term cardiomyocyte engraftment partially regenerates injured heart, which is hypothesized to bring clinical benefits.

The need for allogeneic cells raises the question of how to prevent immune rejection, both from innate immune responses in the acute phase of transplantation or from adaptive immune responses that develop more slowly through the detection of non-self antigens presented by major histocompatibility complexes (MHCs). A current strategy is the collection of iPSCs from patients who have homozygous MHC loci, which results in exponentially more MHC matches with the general population. However, studies in macaque monkeys suggest that MHC matching will be insufficient. In a macaque model of brain injury, immunosuppression was required to prevent rejection of MHC-matched iPSC-derived neurons (8). Similarly, MHC matching reduced the immunogenicity of iPSC-derived cardiomyocytes transplanted subcutaneously or into the hearts of rhesus macaques, but immunosuppressive drugs were still required to prevent rejection (9).

Numerous immune gene editing approaches have been proposed to circumvent rejection, including preventing MHC class I and II molecule expression, overexpressing immunomodulatory cell-surface factors, such CD47 and human leukocyte antigen E (HLA-E) and HLA-G (two human MHC molecules that promote maternal-fetal immune tolerance), or engineering cells to produce immunosuppressants such as programmed cell death ligand 1 (PDL1) and cytotoxic T lymphocyteassociated antigen 4 (CTLA4) (10). These approaches singly or in combination seem to reduce adaptive immune responses in vitro and in mouse models. Overexpressing HLA-G or CD47 also blunts the innate natural killer cellmediated response that results from deleting MHC class I genes (11). However, these manipulations are not without theoretical risks. It could be difficult to clear viral infections from an immunostealthy patch of tissue, and possible tumors resulting from engraftment of PSCs might be difficult to clear immunologically.

Ventricular arrhythmias have emerged as the major toxicity of cardiomyocyte cell therapy. Initial studies in small animals showed no arrhythmic complications (probably because their heart rates are too fast), but in large animals with human-like heart rates, arrhythmias were consistently observed (5, 12). Stereotypically, these arrhythmias arise a few days after transplantation, peak within a few weeks, and subside after 4 to 6 weeks. The arrhythmias were well tolerated in macaques (5) but were lethal in a subset of pigs (12). Electrophysiological studies indicate that these arrhythmias originate in graft regions from a source that behaves like an ectopic pacemaker. Understanding the mechanism of these arrhythmias and developing solutions are major areas of research. There is particular interest in the hypothesis that the immaturity of PSC-cardiomyocytes contributes to these arrhythmias, and that their maturation in situ caused arrhythmias to subside.

A successful therapy for heart regeneration also requires understanding the host side of the equation. PSC-derived cardiomyocytes engraft despite transplantation into injured myocardium that is ischemic with poor blood flow. Although vessels eventually grow in from the host tissue, normal perfusion is not restored. Achieving a robust arterial input will be key to restoring function, which may require cotransplanting other cell populations or tissue engineering approaches (13, 14). Most PSC-mediated cardiac cell therapy studies have been performed in the subacute window, equivalent to 2 to 4 weeks after myocardial infarction in humans. At this point, there has been insufficient time for a substantial fibrotic response. Fibrosis has multiple deleterious features, including mechanically stiffening the tissue and creating zones of electrical insulation that can cause arrhythmias. Extending this therapy to other clinical situations, such as chronic heart failure, will require additional approaches that address the preexisting fibrosis. Cell therapy may again provide an answer because CAR T cells targeted to cardiac fibroblasts reduced fibrosis (15).

Developing a human cardiomyocyte therapy for heart regeneration will push the limits of cell manufacturing. Each patient will likely require a dose of 1 billion to 10 billion cells. Given the widespread nature of ischemic heart disease, 105 to 106 patients a year are likely to need treatment, which translates to 1014 to 1016 cardiomyocytes per year. Growing cells at this scale will require introduction of next generation bioreactors, development of lower-cost media, construction of large-scale cryopreservation and banking systems, and establishment of a robust supply chain compatible with clinical-grade manufacturing practices.

Beyond PSC-cardiomyocytes, other promising approaches include reactivating cardiomyocyte division and reprogramming fibroblasts to form new cardiomyocytes. However, these approaches are at an earlier stage of development, and currently, PSC-derived cardiomyocyte therapy is the only approach that results in large and lasting new muscle grafts. The hurdles to this treatment are known, and likely addressable, thus multiple clinical trials are anticipated.

Acknowledgments: C.E.M. and W.R.M. are scientific founders of and equity holders in Sana Biotechnology. C.E.M. is an employee of Sana Biotechnology. W.R.M. is a consultant for Sana Biotechnology. C.E.M. and W.R.M. hold issued and pending patents in the field of stem cell and regenerative biology.

Read the original here:

Stem cells and the heartthe road ahead - Science Magazine

Stem Cell Therapy Contract Manufacturing Industry, 2019-2030 – Availability of Cutting-Edge Tools & Technologies has Emerged as a Differentiating…

Dublin, Feb. 17, 2020 (GLOBE NEWSWIRE) -- The "Stem Cell Therapy Contract Manufacturing Market, 2019-2030" report has been added to ResearchAndMarkets.com's offering.

This report features an extensive study on contract service providers engaged in the development and manufacturing of stem cell therapies. The study features in-depth analyses, highlighting the capabilities of various stem cell therapy CMOs

Advances in the fields of cell biology and regenerative medicine have led to the development of a variety of stem cell-based therapies for many cardiovascular, oncological, metabolic and musculoskeletal disorders. Driven by the revenues generated from stem cell therapies, the regenerative medicine market is anticipated to generate revenues worth USD 100 billion by 2030.

With a promising pipeline of over 200 stem cell therapy candidates, it has become essential for developers to scale up the production of such therapeutic interventions. Given that stem cell therapy manufacturing requires highly regulated, state-of-the-art technologies, it is difficult for stakeholders to establish in-house expertise for large-scale manufacturing of stem cell therapies.

As a result, stem cell therapy developers have begun outsourcing their manufacturing operations to contract manufacturing organizations (CMOs). Specifically, small and mid-sized players in this sector tend to outsource a substantial proportion of clinical and commercial-scale manufacturing processes to contract service providers. In addition, even big pharma players, with established in-house capabilities, are gradually entering into long-term business relationships with CMOs in order to optimize resource utilization and manage costs.

According to a recent Nice Insight CDMO survey, about 55% of 700 respondents claimed to have collaborated with a contract service provider for clinical and commercial-scale product development requirements. Considering the prevalent trends, we believe that the stem cell therapy manufacturing market is poised to grow at a steady pace, driven by a robust pipeline of therapy candidates and technological advances aimed at mitigating challenges posed by conventional methods of production. Amidst tough competition, the availability of cutting-edge tools and technologies has emerged as a differentiating factor and is likely to grant a competitive advantage to certain CMOs over other players in the industry.

One of the key objectives of the report was to estimate the future size of the market. Based on parameters, such as increase in number of clinical studies, target patient population, anticipated adoption of stem cell therapies and expected variation in manufacturing costs, we have provided an informed estimate of the likely evolution of the market in the mid to long term, for the period 2019-2030.

Amongst other elements, the report includes:

In order to provide a detailed future outlook, our projections have been segmented on the basis of:

Key Topics Covered

1. Preface

2. Executive Summary

3. Introduction

4. Market Overview

5. Regulatory Landscape

6. Stem Cell Therapy Contract Manufacturers in North America

7. Stem Cell Therapy Contract Manufacturers in Europe and Asia-Pacific

8. Partnerships and Collaboration

9. Contract Manufacturing Opportunity Assessment

10. Capacity Analysis

11. Demand Analysis

12. Market Forecast

13. Key Performance Indicators

14. Concluding Remark

15. Executive Insights

16. Appendix 1: Tabulated Data

17. Appendix 2: List of Companies and Organizations

For more information about this report visit https://www.researchandmarkets.com/r/rktm8d

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.comLaura Wood, Senior Press Managerpress@researchandmarkets.comFor E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900

Read the original:

Stem Cell Therapy Contract Manufacturing Industry, 2019-2030 - Availability of Cutting-Edge Tools & Technologies has Emerged as a Differentiating...

FDA Scoffs at Third Way Forward in Stem Cell Therapy – Pain News Network

Gimble and his co-authors recommend the FDA re-evaluate how it categorizes tissues as structural or cellular to recognize the different safety profiles of stem cells products. They also think the FDA should work with accreditation agencies like AABB and FACT to develop meaningful accreditation standards, along with a national registry for stem cell therapies.

This measured third way seeks to carve a compromise between the FDAs regulationist faction and wild west stem cell providers -- a new ideological center that synthesizes the aspirations of two opposing parties in an effort to achieve a compromise.

It must be stated that there are serious questions as to whether the authors proposed polarity is in fact an artifice created for the specific purpose of legitimizing their third way. Upon serious inspection, the authors stated dangers of stem cell clinics may actually be a disingenuous straw man created for their own business interests.

To promote their own agenda and to gain favor with the FDA, Gimble and his co-authors seem to have thrown stem cell clinicians like Dr. Mark Berman under the proverbial bus. Berman, who is a defendant in a FDA lawsuit over his use of autologous cells, recently won a victory in federal court. The judge found that the FDA may not have regulatory authority over Bermans procedures and that a trial needs to be held to resolve the issue.

Nevertheless, the impetus behind the authors recommendations is to move forward with bringing stem cells to patients faster and in a safer manner. Regrettably, the FDA does anything but take the authors seriously. In a lengthy response to the Gimble article, Dr. Peter Marks, Director of the FDAs Center for Biologics Evaluation and Research, merely reiterates the agencys firmly-established regulationist position.

After commending the authors for their desire to accelerate the scientific investigation and development of stem cell therapies, Marks demonstrates the FDAs backward-looking posture by stating the agencys regulation of stem cells is distinct from the practice of medicine and should be left alone.

This is an existing paradigm that has been in place for decades, Marks wrote. Autologous cellular therapies do hold tremendous promise, but they will only find their way into routine clinical practice to bring benefit to all patients if they are held to the same standards to demonstrate safety and efficacy as other unproven medical products.

Marks attempts to bolster his argument by citing patient safety, the dearth of research on adipose-derived stem cells and the unethical bad actor clinics that exploit desperate patients. However, the spirit of his position reveals a resistance to any sort of change whatsoever.

Marks and the FDA are living in the past. They consider your cells to be unproven medical products. Apparently, they have yet to realize that the stem cell poles have already shifted.

A. Rahman Ford, PhD, is a lawyer and research professional. He is a graduate of Rutgers University and the Howard University School of Law, where he served as Editor-in-Chief of the Howard Law Journal. Rahman lives with chronic inflammation in his digestive tract and is unable to eat solid food. He has received stem cell treatmentin China.

Read the original post:

FDA Scoffs at Third Way Forward in Stem Cell Therapy - Pain News Network

Tackling the Challenges in Cell and Gene Therapy… – Labiotech.eu

The excitement about cell and gene therapies is almost tangible within the biotech and pharma industry. Over 950 companies are actively developing advanced therapies, which are expected to make exceptional improvements to peoples lives in the next decade. Although hopes are high, the industry still faces a number of challenges in cell and gene therapy manufacturing, mainly around being able to deliver these often difficult to make, complex treatments at the scale needed to meet patient demand.

The unprecedented growth of the industry, alongside the need to develop scalable manufacturing strategies, has led to a number of challenges that need to be addressed urgently. Previously, patient numbers were so small that processes were highly manual and required numerous skilled operators. However, the recent success of early gene therapy trials means upscaling now needs to be considered right from the start.

In the early days the aim was just to get to the clinic, said Lindsey Clarke, Head of Cell and Gene Therapy EMEA at Bio-Techne. Scale didnt come into it so much, but now the conversations we are having focus much more on making these complex therapies at a scale needed for a commercial medicine. There are increased efforts on finding solutions that dont just work for trials with 10 patients, but will still work at 1000 times that scale.

Life science tools and technology provider, Bio-Techne, has made it its mission to further support the cell and gene therapy industry by channeling its expertise into developing technologies that can help to scale manufacturing processes. The companys commitment is highlighted by its recent investment into a new good manufacturing practice (GMP) manufacturing facility in St Paul, Minnesota, US, that will focus on producing raw materials for use in cell and gene therapy applications.

We have realized that if all our customers are to be successful with their therapies then there will be a huge demand for raw materials, Clarke explained. So weve started building that capability, ahead of time. But its not just about supply, we are also innovating, from simple things like looking closely at the format our products come in and making them more compatible with large-scale manufacturing to whole new product ranges.

Bio-Technes investment in the new GMP manufacturing facility is a solution to meet the growing demand for raw materials needed for cell and gene therapy manufacturing. But its just one piece of a large puzzle: cell and gene therapy developers also need to consider the complex logistics required to deliver their therapies to the clinic, particularly when its an autologous therapy.

The process from the patient to the clinician, to the apheresis collection, to the manufacturing site, then the complex manufacturing process and then delivery back to the patient is highly complex.

Another key challenge closely related to upscaling is the great risk of human error in manual processes. Many of the cell and gene manufacturing processes currently in place have been developed with small patient numbers in mind and involve manual steps.

Humans are an excellent source of error and risk, explained Clarke. When youre manufacturing in a GMP environment, you need highly-skilled, trained operators and there is a shortage of them out there. Automation is going to be key to address this issue. Not only does it reduce the manpower that is required, but it can also streamline the processes and make them less risky, more scalable, and reproducible as well, Clarke added.

With cell and gene therapy products, various analytical methods are used to assess critical quality attributes during development and manufacturing. These reflect the identity, potency, purity, safety, and stability of the product. However, such methods are frequently complex, non-standardized, time-consuming, and performed manually by trained operators.

Organizations such as Cell and Gene Therapy Catapult have called for the development of new analytical solutions for quality testing of advanced therapies throughout the manufacturing process. More automated analytical technologies have the potential to increase facility throughput and make quality control (QC) faster, less error-prone, more reproducible, and more GMP compliant.

Although Bio-Techne has a long-standing history of developing quality proteins, antibodies, small molecules, and immunoassays, it has expanded into automated protein analytical technologies in recent years.

For viral and non-viral vectors, Bio-Technes ProteinSimple branded platforms are rapidly being adopted by cell and gene therapy developers for assessment of vector identity, purity, and stability. Compared to traditional methods like Western blot, SDS-PAGE, and ELISA, ProteinSimples technology platform is based on capillary electrophoresis and microfluidics and provides a fully automated and accurate quantitative analysis of vectors.

We are also seeing Micro-Flow Imaging (MFI), a more common image-based analytical platform in biologics, used to characterize subvisible particles for quality control of cell and gene therapy products, explained Kamar Johnson, Commercial Development Manager in Cell and Gene Therapy at Bio-Techne. These automated platforms offer ease of use, rapid time to result, enhanced reproducibility and software that meets GMP requirements.

Collaboration lies at the heart of successful innovation. It is especially important at the interface between process development and manufacturing, said Johnson.

Not everyone is an expert in everything, we all have our particular niches of expertise, added Clarke. We believe that we need to collaborate to get the innovation that will help change the way we manufacture cell and gene therapies. Collaboration is the key to solving the challenges of the cell and gene therapy industry.

On that note, Bio-Techne recently partnered with Fresenius Kabi and Wilson Wolf to form a new joint venture that provides manufacturing technologies and processes for the development and commercialization of new cell and gene therapies.

The collaboration combines Bio-Technes expertise of proteins, reagents, media, and gene editing technologies with Fresenius Kabis Lovo cell processing system and the bioreactor expertise from Wilson Wolf with its G-Rex technology that is designed as a scalable and practical platform for personalized cell therapies.

As processes develop and technologies evolve, the cell and gene therapy space will be confronted with new challenges. At Bio-Techne, the team is keeping an eye out for interesting trends that might affect the industry.

I see the induced pluripotent stem cell (iPSC) therapy field continuing to grow with more allogeneic cell therapies being developed, says Johnson. Allogeneic manufacturing is potentially less complicated than autologous manufacturing due to the ability to provide off-the-shelf products when patients need them.

Although the challenges in cell and gene therapy manufacturing remain a problem, companies like Bio-Techne are establishing quicker, simpler, and more automated options within quality control, manufacturing, and process development.

Wherever we go, we see newer technologies supporting cell and gene therapy manufacturing, says Clarke. Within our industry, changes come so rapidly and the treatments have shown so much promise that there is a lot of focus on cell and gene therapies. This puts a lot of pressure on us as an industry to provide these treatments. I believe that collaboration is the key to tackling this problem.

To learn more about the challenges in cell and gene therapy manufacturing and how to solve them, visit Bio-Technes website or get in touch with the experts here!

Images via Shutterstock.com

Author: Larissa Warneck

The rest is here:

Tackling the Challenges in Cell and Gene Therapy... - Labiotech.eu

Experimental study speeds up bone healing with 2 common medications – New Atlas

A new proof-of-concept study has found a combination of two drugs, already approved by the FDA for other uses, may boost the release of stem cells from bone marrow and accelerate the healing of broken bones. Only demonstrated in animals at this stage, the researchers suggest clinical trials could progress rapidly considering the drugs have already been demonstrated as safe in humans.

"The body repairs itself all the time, says corresponding author on the study Sara Rankin. We know that when bones break they will heal, and this requires the activation of stem cells in the bone. However, when the damage is severe, there are limits to what the body can do of its own accord.

A great deal of current research is focusing on mesenchymal stem cell (MSC) therapies. MSCs are a type of adult stem cell that can grow into a variety of different cell types including muscle, fat or bone. Many current MSC treatments in development involve extracting a small number from a patient, growing them in laboratory conditions, then injecting them back into the patient.

The new research set out to investigate whether any currently approved drugs can function to mobilize the bodys natural ability in releasing MSCs, with a view on speeding up healing of bone fractures. A study published in the journal npj Regenerative Medicine, describes the testing of two already approved drugs in a rodent spinal injury model.

The two drugs tested were an immunostimulant called Plerixafor, used to stimulate the release of stem cells from bone marrow in cancer patients, and a beta-3 adrenergic agonist developed to help bladder control.

The results suggest the duo of drugs mobilize MSCs into the bloodstream and speed up the process of bone formation and healing by enhancing the binding of calcium to the injury site. Tariq Fellous, first author on the new study, suggests the next step is to investigate whether this drug combination enhances blood MSC levels in human subjects.

We first need to see if these medications release the stem cells in healthy volunteers, before we can then test them in patients with fractures, says Fellous. We have the drugs and know they are safe to use in humans - we just need the funding for the human trials.

The researchers say prior studies have identified circulating MSCs increase in volume following injuries such as burns, bone fractures, and even heart attack. The hypothesis is that the release of MSCs is a physiological process aiding general regeneration following injury, and if circulating numbers of MSCs could be pharmacologically enhanced then a variety of types of tissue regeneration could be accelerated.

It is important to note the current study only examined increases in circulating MSCs and the rate of spine injury healing compared to no drug treatment. The current research offers no indication whether the drug duo influences nerve healing or restores movement.

So, more work is certainly necessary to understand how clinically useful these results actually are. However, as the studys co-first author Andia Redpath notes, this re-purposing of existing medicines to boost stem cell activity is an easier, cheaper, and more efficient way to enhance healing compared to other, more complex and time-consuming, stem cell treatments in development.

Rather than devising new stem cell treatments from scratch that involve lengthy and expensive trials, our approach harnesses the power of the bodys own stem cells, using existing drugs, says Redpath. We already know the treatments in our study are safe, its now just a matter of exploring further if they help our bodies heal.

The new study was published in the journal npj Regenerative Medicine.

Source: Imperial College London

The rest is here:

Experimental study speeds up bone healing with 2 common medications - New Atlas

Austin Aries Announces Position With Stem Cell Therapy Company, Says He Met With AEW Regarding Partnership – LordsofPain.net

Former IMPACT world champion Austin Aries was spotted backstage at Wednesdays taping of AEW Dynamite from Atlanta. Aries later told Bodyslam.net that he was representing the new stem cell therapy he works for, BioXcellerator, and did in fact meet with AEW officials, as well as Diamond Dallas Pages DDPY brand.

I work for BioX. I did have meetings about partnerships and collaborations with both DDP and DDPY Brand as well as AEW.

Aries officially announced his new position, which is as Director of the Athletic Performance Division, on Instagram.

BIG ANNOUNCEMENT!!! Many of you know that I went down to Medellin, Colombia in December for @bioxcellerator_ #stemcelltherapy, and now after a couple months, my neck and lower back feel really good. I was honestly so impressed with the entire @bioxcellerator_ operation. So much so, that upon returning I had conversations about joining the @bioxcellerator_ team in some capacity. With that, I am EXTREMELY EXCITED TO ANNOUNCE that I have officially joined BioXcellerator as Director Of Athletic Performance Division. My role will be to continue connecting high level athletes, entertainers and influencers with all the amazing benefits of @bioxcellerator_ #stemcelltherapy. As someone whose passion is helping people, I couldnt pass up the opportunity to be a part of this company that is changing lives with their cutting edge #stemcelltherapy. So, anyone whos been thinking about, or interested in finding out more about BioXcellerator stem cell therapy, Im your guy! Please DM or email me at Austin@BioXcellerator.com. Heres to all our improved health and happiness in 2020 and beyond!

View this post on Instagram

BIG ANNOUNCEMENT!!! . Many of you know that I went down to Medellin, Colombia in December for @bioxcellerator_ #stemcelltherapy, and now after a couple months, my neck and lower back feel really good. I was honestly so impressed with the entire @bioxcellerator_ operation. So much so, that upon returning I had conversations about joining the @bioxcellerator_ team in some capacity. . With that, I am EXTREMELY EXCITED TO ANNOUNCE that I have officially joined BioXcellerator as Director Of Athletic Performance Division. My role will be to continue connecting high level athletes, entertainers and influencers with all the amazing benefits of @bioxcellerator_ #stemcelltherapy. As someone whose passion is helping people, I couldnt pass up the opportunity to be a part of this company that is changing lives with their cutting edge #stemcelltherapy. . So, anyone whos been thinking about, or interested in finding out more about BioXcellerator stem cell therapy, Im your guy! Please DM or email me at Austin@BioXcellerator.com. Heres to all our improved health and happiness in 2020 and beyond! . . #bioxcellerator #bioxmen #bioxwomen #stemcell #stemcells #stemcelltherapy #medellin #colombia

A post shared by Austin Aries (@austinhealyaries) on Feb 17, 2020 at 8:49am PST

Home NEWS Austin Aries Announces Position With Stem Cell Therapy Company, Says He Met With AEW Regarding Partnership

Originally posted here:

Austin Aries Announces Position With Stem Cell Therapy Company, Says He Met With AEW Regarding Partnership - LordsofPain.net

Meet 20 European Immuno-Oncology Companies that are Fighting… – Labiotech.eu

With the success of CAR T-cell therapies and other innovative medicines in this area, immuno-oncology has become a buzzword in biotech, with more and more companies starting up in Europe and elsewhere. With so many players involved, it can be hard to know who is doing what. Here are 20 European companies we think stand out and are leading the revolution in cancer medicine.

Although immunotherapies to treat cancer have been around for decades, new approaches are popping up every other day. After all, enlisting the immune system to fight cancer remains an extremely promising therapeutic strategy. There are so many companies focusing on different kinds of immunotherapies that it was quite a challenge to choose our favorites. We therefore enlisted the help of experts in the industry to select the following 20 immuno-oncology companies in Europe as our top picks. As ever, these are in no particular order.

Founded in Abingdon, UK, in 2008, Adaptimmune develops enhanced T-cell therapies that support the immune system in detecting and targeting cancer cells. Interestingly, its SPEAR T cell technology can target a variety of solid tumors a feat that is not easy to achieve, as solid tumors have a highly complex tumor microenvironment that many immunotherapies find difficult to penetrate.

The companys technology can identify and select T cell receptors (TCRs) that are more likely to improve the patients immune response and result in the effective binding of cancer cells. In January 2020, Adaptimmune and Japanese company Astellas agreed to co-develop and co-commercialize stem-cell-derived allogeneic chimeric antigen receptor (CAR)-T and TCR T cell therapies, which means that they not only treat one specific patient but a large number of patients with a particular cancer type. The deal was worth 806M.

ADC Therapeutics works in the area of antibody-drug conjugates (ADCs). Since being founded in 2011 in Lausanne, Switzerland, ADC Therapeutics has raised 514M ($558M) to advance its immuno-oncology therapies. The companys proprietary ADCs combine monoclonal antibodies that are specific to targets on the surface of tumor cells with a specific class of toxins called pyrrolobenzodiazepine (PBD) dimers.

The PBD dimer is released inside the tumor cells and binds to the tumor DNA, which blocks the division of the tumor cells and eventually kills them. ADC Therapeutics currently has two ADCs for liquid tumors in pivotal phase II studies, and one ADC targeting solid tumors in phase Ib. In January 2020, the company announced the positive results of its phase II trial of its leading ADC in patients with relapsed or refractory diffuse large B cell lymphoma.

Yet another direction in the treatment of cancer via the immune system is taken by Heidelberg-based company Affimed Therapeutics. Founded in 2000, the company focuses on the innate immune system. Using its ROCK platform, Affimed develops multi-specific antibodies called cell engagers.

Innate cell engagers can bind to the patients innate immune cells, including natural killer cells and macrophages, while simultaneously binding to specific tumor cells. As a result, the patients own immune systems can attack and kill the cancer cells. The companys lead candidate is currently in phase II for a number of liquid tumors.

Based in London, UK, and founded in 2014 as a spin-out from the University College London, Autolus Therapeutics uses CARs and TCRs to reprogram T cells so they recognize and consequently kill tumor cells. In January 2020, the company revealed the closure of its public offering on the Nasdaq with net proceeds of 68.4M ($74.2M).

Autolus other news in January was the announcement of the clinical progress of its next-generation programmed T cell therapy. It is currently in Phase I/II for the treatment of adults with relapsed or refractory diffuse large B cell lymphoma. The results showed no neurotoxicity and a manageable safety profile.

BioNTech has a much larger pipeline that contains CARs, TCRs, recombinant cytokines, and optimized mRNA. Founded in Mainz, Germany, in 2008, the company is one of the largest biotechs in Europe. Its pipeline is full to bursting with a variety of immuno-oncology therapies based on mRNA, antibodies, and CAR-T cells.

In July 2019, BioNTech raised one of the biggest ever funding rounds of a European biotech with a whopping 290M Series B. However, in October of that same year, the companys Nasdaq IPO, which was initially estimated to raise around 725M, resulted in pricing at only 141M due to poor market conditions in the US.

Based in Paris, France, and founded in 1999, Cellectis is also focusing on CART-cell therapy. It is working on a novel type of CART therapy known as Universal CARTs (UCARTs). Unlike the two approved CAR-T therapies, Novartis Kymriah and Gileads Yescarta, UCARTs are allogeneic so rather than being personalized, they can treat a large number of patients with a particular cancer type.

In November 2019, Cellectis announced that it had won the European patent challenge for the use of CRISPR-Cas9 for gene editing T cells. This process will help the company further develop its UCART platform. To date, six of its main UCART product candidates are in Phase I clinical trials.

As another biotech giant, Celyad is also working in the field of CART-cell therapies but is focusing on the NKG2D receptor. Founded in 2004 in Mont-Saint Guibert, Belgium, the companys lead immuno-oncology candidate uses the NKG2D receptor. NKG2D can bind to eight different ligands that are naturally found on cancer cells present in 80% of solid and liquid malignancies.

Something cool about NKG2D is that the ligands that it recognizes are also expressed by the tumor microenvironment, which comprises the blood vessels that support the tumor and the cells that make sure the tumor can evade the immune system. As a result, the lead candidate can target and kill the tumor as well as cleaning up its microenvironment. The candidate is currently in phase I.

Spun-off from the Babraham Institute in Cambridge, UK, in 2007, Crescendo Biologics develops targeted T-cell enhancing therapeutics with the aim of tackling difficult-to-treat cancers. The companys Humabody therapies are small, multi-specific antibody fragments that can penetrate tumor tissue in a way that conventional antibodies cannot.

Crescendo Biologics lead proprietary candidate is a bispecific T-cell engager targeting the prostate-specific membrane antigen. It can selectively activate tumor-specific T cells within the tumor microenvironment. It is currently advancing towards clinical development.

As a spring chicken among other European immuno-oncology companies, we felt Ervaxx deserved a mention here because it develops cancer vaccines and cell therapies targeting dark antigens normally silent genes that are expressed in cancer cells. Founded in 2017 in London, UK, Ervaxx recently made headlines when it got its hands on the license of an exciting new preclinical stage universal cancer immunotherapy.

In early January 2020, a group of researchers at Cardiff University discovered a new type of T cells that have the potential to attack a wide range of cancers, such as leukemia and melanoma. Ervaxx is continuously expanding its repertoire of Dark Antigens. Using these, the company is working on a pipeline of off-the-shelf cancer vaccines and TCR-based therapies.

Founded in 2008 in Copenhagen, Denmark, Evaxion takes a very different approach to fighting cancer: using artificial intelligence (AI) to develop immunotherapies. The company has developed two AI platforms that can identify and optimize epitopes and antigens that are capable of eliciting strong immune responses against cancer and infectious diseases.

The companys PIONEER platform is used for the development of personalized cancer immunotherapies. In April 2019, it announced the beginning of phase I with the dosing of the first patient with its lead candidate, a therapeutic vaccine. Evaxion closed the year by successfully raising 16M ($17M).

GammaDelta Therapeutics, founded in 2016, takes another approach to immuno-oncology therapies. The London-based company focuses on gamma delta T cells. Unlike alpha beta T cells which are commonly used in CAR-T therapy, gamma delta T cells are a part of the innate immune system. In short, this means that gamma delta T cells are already pre-programmed to identify and kill cells that are modified by cancer. The company is currently advancing its allogeneic gamma delta T cell therapies through preclinical development.

In October 2019, GammaDelta Therapeutics announced the formation of the spinout company Adaptate Biotherapeutics. Adaptate will be developing therapeutic antibodies that can modulate the activity of gamma delta T cells with the aim of triggering an immune response to fight cancer.

Danish biotech Genmab had an exciting start to the new year. In January 2020, one of the companys lead candidates daratumumab, a monoclonal antibody, received marketing authorization by the EMA. Marketed as DARZALEX, it can be used in combination with bortezomib, thalidomide, and dexamethasone to treat multiple myeloma.

Founded in Copenhagen in 1999, Genmab focuses on the development of antibody therapies against cancer. In December 2019, Genmab signed a deal with German biotech CureVac to develop mRNA drugs that can produce antibodies within the patient, which is an exciting development.

Heidelberg Pharma, formerly known as Wilex, was founded in 1997 in Heidelberg, Germany. The company focuses on ADCs. It has an exclusive license agreement with the Max Delbrck Center for Molecular Medicine in the Helmholtz Association in Berlin that includes a number of surface proteins found in multiple myeloma cells called B cell maturation antigen (BCMA).

Heidelberg Pharmas lead candidate targets BCMA and is currently advancing through the preclinical stage. It is an ADC that consists of a BCMA antibody, a specific linker, and the toxin amanitin, one of the deadliest toxins found in several mushroom species.

Founded in 2011, Austrian company Hookipa Pharma engineers arenaviruses to deliver tumor-specific genes to dendritic cells. Dendritic cells naturally activate killer T cells by delivering the tumor-specific antigens to them, which triggers an immune response. HOOKIPA Pharmas co-founder, Rolf Zinkernagel, actually received the Nobel Prize for Physiology or Medicine in 1996 for his work on how killer T cells can recognize virus-infected cells.

Hookipas leading immuno-oncology therapy is currently progressing through phase I. In February 2019, the company closed a Series D financing round for 33.2M ($37.4M). The funding is being used to boost the clinical development of its immunotherapies for cancer and infectious diseases based on its proprietary arenavirus platform.

This French company develops antibody therapies to fight cancer. Marseille-based ImCheck has developed a pipeline of monoclonal antibodies that target specific checkpoint molecules of the butyrophilin (BTN) family, which engage gamma delta T cells. As part of the innate immune system, gamma delta T cells fight cancer cells naturally.

ImChecks lead drug candidate, an anti-BTN3 antibody that targets solid tumors, is expected to enter phase I in 2020. In order to fund this trial and further boost the development of immunotherapies, ImCheck closed a series B funding round in December 2019 worth 48M.

Immatics was founded in 2000 in Tbingen, Germany. The company develops personalized immuno-oncology therapies by engineering patient T cells to express TCRs, which specifically target the patients cancer. Unlike CAR-T therapies that generally target surface proteins, Immatics immunotherapy can also target proteins within cancer cells, which makes the cancer cells more vulnerable and accessible to the immune system.

In August 2019, American company Celgene and Immatics signed a deal worth more than 1.35B ($1.5B) to further develop its immuno-oncology therapies. In three cancer immunotherapy programs, Immatics will develop leading cell immunotherapy candidates for solid tumors, while Celgene has the option to co-develop the candidates or take over the development altogether.

Based in Oxfordshire, UK, and founded in 2008, Immunocore also focuses on TCRs. Its ImmTAC (immune mobilizing monoclonal TCRs against cancer) technology is based on a new class of bi-specific biologics that can activate a specific T cell response in cancer cells.

In December 2019, Immunocore announced the start of the first-in-human clinical trial of its third bispecific, which was developed using the ImmTAC technology platform. Immunocore has collaborations with a number of partners, including AstraZeneca, Genentech, GSK, and Eli Lilli.

Medigene also focuses on TCRs. However, this company develops modified TCRs called TCR-Ts, as well as dendritic cell vaccines (DCs), and T cell-specific antibodies (TABs).

In January 2020, Medigene announced positive results after a two-year phase I/II for its DC vaccine in patients with acute myeloid leukemia (AML). Moreover, its leading TCR-T candidate is currently being prepared for phase II clinical trials. Medigene was founded in 1994 in Martinsried, Germany.

As a neighbor of Medigene, MorphoSys is also based in Martinsried, Germany. It was founded in 1992. The company is one of the very few European biotechs valued at over 1B. MorphoSys develops antibody therapies for numerous conditions.

The companys lead immuno-oncology candidate tafasitamab is a humanized monoclonal antibody that targets CD19, an antigen mainly expressed by various B cell-derived blood cancers, such as non-Hodgkins lymphoma, diffuse large B cell lymphoma, and chronic lymphocytic leukemia. This candidate is being co-commercialized by Imcyte. Other partners of MorphoSys include Novartis, Roche, GSK, and Roche.

Another company focusing on ADCs is NBE Therapeutics. This companys goal is to target solid tumors. Based in Basel, Switzerland, and founded in 2012, NBE Therapeutics has developed a technology that uses an enzyme to attach small molecule drugs to monoclonal antibodies. This approach is different from conventional ADCs that are usually generated using a chemical junction, which can be unstable at times.

The companys lead candidate, an ADC for the treatment of triple-negative breast cancer, lung, and ovarian cancer, is expected to reach phase I in 2020.

Images via Elena Resko & Shutterstock.com

Read the original:

Meet 20 European Immuno-Oncology Companies that are Fighting... - Labiotech.eu

Transplant for Szary Syndrome is Patient’s First Step in Returning to the Dance Floor – Dana-Farber Cancer Institute

The first time Bill Cronin Googled his own cancer diagnosis in 2016, his heart sank. He had Szary syndrome, a rare and aggressive form of cutaneous T-cell lymphoma and staring back at him were countless articles predicting a negative prognosis.

However, after receiving a stem-cell transplant at Dana-Farber/Brigham and Womens Cancer Center, Cronin is returning to the life he enjoyed before cancer.

Im at a place I never thought Id get to, Cronin says.

In 2015, Cronin, then 60, started feeling incredibly itchy and developed an accompanying rash. He went to his dermatologist, who diagnosed him with eczema and told him to return in five months. The rash continued to grow, however, and at the five month mark, Cronins dermatologist encouraged him to undergo further testing at Dana-Farber.

A blood test revealed that Cronins T-cells a type ofwhite blood cells that make up part of the immune system had becomecancerous. In the case of Szary syndrome, lymphoma cells will circulatethrough the blood stream and deposit in different areas of the skin. This willgenerally lead to a full-body rash and intense itchiness.

Cronin would need a stem cell transplant to combat the disease, but before he could receive one, his care team had to get him into remission. Patients who do not achieve remission prior to transplant have a high chance of relapsing.

When they first told me everything, I was really scared, says Cronin. But I knew I was in one of the best places in the world to figure out and treat this rare disease.

Cronins pre-transplant care was spearheaded by oncologists David Fisher, MD, and Nicole LeBoeuf, MD, MPH, clinical director of Cutaneous Oncology at Dana-Farber, with his transplant conducted by Corey Cutler, MD, MPH, medical director of the Adult Stem Cell Transplantation Program at Dana-Farber. Initially, Cronins disease was incredibly resistant; for nearly three years, mainstay drugs including steroids, monoclonal antibodies, and enzyme blockers all failed to put his disease into remission.

Ultimately, it would take a new drug, mogamulizumab (a type of immunotherapy that directly kills T-cells involved with Sezary Syndrome) to get Cronins disease into remission.

In May 2019, Cronin was cleared to undergo an allogeneic transplant, a type of transplant that uses a donors stem cells, in this case, Cronins brother. Since his transplant Cronin has remained in remission.

We had to use all of our big guns to get him totransplant, but Im pleased with where we are now, says Cutler.

I know the situation can always change, but it was great tobe able to share some good news with my family and friends, adds Cronin.

Patients like Cronin serve as a reminder of how stem cell transplants have improved and continue to impact patient outcomes, Dana-Farber experts note. Initially offered to only an incredibly small patient population when first performed at Dana-Farber in the 1970s, research advancements have, and continue to, broaden who is eligible for a transplant. In 2019, Dana-Farber/Brigham and Womens Cancer Center (DF/BWCC) surpassed 10,000 total adult transplants.

This milestone indicates our success as a program and our volume has allowed us to do the research to help move the field forward rather impressively, says Joseph Antin, MD, chief emeritus of Adult Stem Cell Transplantation at DF/BWCC.

In 1996, Dana-Farber Cancer Institute and Brigham and Womens Hospital merged their then separate transplant centers. By pooling together physical and intellectual resources, the new combined program was able to more than double the number of transplants each hospital could perform individually.

We always felt collaboration was better than competition, explains Robert Soiffer, MD, vice chair of Medical Oncology for Hematological Malignancies and chief of the Division of Hematologic Malignancies, who oversaw the merger with Antin. Each side could learn from the other, and that helped to catapult us into the leadership position we have today.

The Stem Cell Transplantation Program is also bolstered by the Connell and OReilly Families Cell Manipulation Core Facility (CMCF), which was established in 1996. The state-of-the-art center, led by Jerome Ritz, MD, not only processes the stem cells for transplant; it also assists researchers in developing new cell-based therapies for patients.

Another key component to the programs success has been the creation of the Ted and Eileen Pasquarello Tissue Bank. The Pasquarello Tissue Bank receives, processes, banks, and distributes research samplesof blood, bone marrow, and other tissues. Through a database overseen by Vincent Ho, MD, the Institute is able to log, assess, and later review every patients disease, including all complications and mutations. This technology allows researchers to explore the genetic makeup of past donors and better understand why a transplant was or was not successful.

Were still learning from biological specimens we collected 20 years ago, and it will continue to impact care 20 years from now, Soiffer says.

Today, there is a continuous push to develop new and more precise therapies to complement and improve stem cell transplants. The hope is to bring new treatment options to patients like Cronin who are facing rare and difficult diseases.

Before his diagnosis, Bill, and Barbara Finney, his partner ofnearly 30 years, were avid English Country dancers. English Country dancingevolved from the court dances of Europe in the early 17th century, and Croninand Barbara have friends from all over the country who share their passion forit.

While Cronin isnt dancing just yet, as hes stillrecovering from his transplant, he says he couldnt have gotten through thiswithout his partner on the dance floor and in life.

Barbara has been amazing and has helped take care ofeverything I couldnt do, he adds. Ive been fortunate and privileged to notonly have her, but to have been able to come to Dana-Farber.

See more here:

Transplant for Szary Syndrome is Patient's First Step in Returning to the Dance Floor - Dana-Farber Cancer Institute

Animal Stem Cell Therapy Market 2020-2026: Product Types, by Applications, By Market Trends, Market Reserach Report – Keep Reading

Our latest research report entitle Global Animal Stem Cell Therapy Market provides comprehensive and deep insights into the market dynamics and growth of Global Animal Stem Cell Therapy Industry. Latest information on market risks, industry chain structure, Animal Stem Cell Therapy cost structure and opportunities are offered in this report. The entire industry is fragmented based on geographical regions, a wide range of applications and Global Animal Stem Cell Therapy Market types. The past, present and forecast market information will lead to investment feasibility by studying the crucial Global Animal Stem Cell Therapy Industry growth factors.

Get FREE Sample Report Copy @ https://www.globalmarketers.biz/report/life-sciences/2018-global-animal-stem-cell-therapy-industry-research-report/118224 #request_sample

Global Animal Stem Cell Therapy Market Analysis By Major Players:

VETSTEM BIOPHARMAMediVet BiologicJ-ARMCelavetMagellan Stem CellsU.S. Stem CellCells Power JapanANIMAL CELL THERAPIESAnimal Care StemCell Therapy SciencesVetCell TherapeuticsAnimacelAratana Therapeutics

Global Animal Stem Cell Therapy Market Analysis By Geographical Zones:

Europe Market (Germany, France, Italy, Russia and UK)

North America Market (Canada, USA and Mexico)

Latin America Market (Middle and Africa).

Animal Stem Cell Therapy Market in Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Asia-Pacific Market (South-east Asia, China, India, Korea and Japan).

Global Animal Stem Cell Therapy Market news, plans & policies, market drivers, analysis of upstream raw material suppliers and downstream buyers of Animal Stem Cell Therapy is carried out in this report. Global Animal Stem Cell Therapy Industry forecast study enlists the market value (in USD) and volume forecast for each region, product type, and applications.

Types Of Global Animal Stem Cell Therapy Market:

DogsHorsesOthers

Applications Of Global Animal Stem Cell Therapy Market:

Veterinary HospitalsResearch Organizations

Inquiry Here For Detail Report @ https://www.globalmarketers.biz/report/life-sciences/2018-global-animal-stem-cell-therapy-industry-research-report/118224 #inquiry_before_buying

To Provide A Clear Global Animal Stem Cell Therapy Market Structure The Report Is Divided Into 12 Chapters As Follows:

Explore Full Report With Detailed TOC Here @ https://www.globalmarketers.biz/report/life-sciences/2018-global-animal-stem-cell-therapy-industry-research-report/118224 #table_of_contents

Major points from Table of Contents for Global Animal Stem Cell Therapy Industry 2020 Market Research Report include:

1 Market Overview

2 Global Animal Stem Cell Therapy Market Competition by Manufacturers

3 Global Animal Stem Cell Therapy Capacity, Production, Revenue (Value) by Region (2020-2026)

4 Global Animal Stem Cell Therapy Industry Supply (Production), Consumption, Export, Import by Region (2020-2026)

5 Global Animal Stem Cell Therapy Production, Revenue (Value), Price Trend by Type

6 Global Animal Stem Cell Therapy Market Analysis by Application

7 Global Animal Stem Cell Therapy Industry Manufacturers Profiles/Analysis

8. Animal Stem Cell Therapy Manufacturing Cost Analysis

9 Industrial Chain, Sourcing Strategy and Downstream Buyers

10 Marketing Strategy Analysis, Distributors/Traders

11 Market Effect Factors Analysis

12 Global Animal Stem Cell Therapy Market Forecast (2020-2026)

13 Research Findings and Conclusion

14 Appendix

Explore Full Report With Detailed TOC Here @ https://www.globalmarketers.biz/report/life-sciences/2018-global-animal-stem-cell-therapy-industry-research-report/118224 #table_of_contents

The rest is here:

Animal Stem Cell Therapy Market 2020-2026: Product Types, by Applications, By Market Trends, Market Reserach Report - Keep Reading

34 years with a new heart and counting – MDJOnline.com

Whenever Harry Wuest has a doctors appointment in northern Atlantas hospital cluster dubbed Pill Hill, he makes sure to stop by the office of Dr. Douglas Doug Murphy for a quick chat.

And Murphy, unless hes tied up in the operating room, always takes a few minutes to say hello to his former patient. Remember when ... ? is how the conversation typically starts, and its always tinged with laughter, often joyful, sometimes bittersweet.

Its a reunion of two men who shaped a piece of Georgias medical history.

Almost 35 years ago, Murphy opened the chest of Wuest and sewed in a new heart, giving him a second shot at life. Wuest was the third heart transplant patient at Emory University Hospital.

Tall, lanky, with short curly hair and a quiet demeanor, Wuest is the longest-surviving heart transplant recipient in Georgia and one of the longest-surviving in the world. The 75-year-old accountant still plays golf twice a week and only recently went from working full-time to part-time. My heart is doing just fine, he says.

Murphy is now the chief of cardiothoracic surgery at Emory Saint Josephs Hospital and still in the operating room almost every day. He has moved on to become the worlds leading expert in robotically assisted heart surgery.

Harry Wuest is originally from Long Island, New York. After a stint in the Air Force, he moved to Florida to work and go to school. He wanted to become a physical education teacher. Then, in 1973, he fell ill. It started with some pain on his left side. He didnt think much of it, but when he got increasingly winded and fatigued, he went to see a doctor.

Several months and numerous specialists later, he received the diagnosis: Cardiomyopathy, a disease of the heart muscle that can make the heart become enlarged, thick and rigid, preventing it from pumping enough blood through the body.

They didnt know how I got it, says Wuest, sitting back in a brown leather armchair in the dark, wood-paneled living room of his Stone Mountain home. Maybe it was a virus. And back then, there wasnt much they could do to treat it, except bed rest.

For the next 12 years, Wuest lived life as best as he could. He got a degree in accounting from the University of Central Florida and worked for a real estate developer. There were good days, but there were more bad days. He was often too weak to do anything, and his heart was getting bigger and bigger.

Emorys first transplant surgeon

The first successful human-to-human heart transplant was performed in Cape Town, South Africa, in 1967 a medical breakthrough that catapulted the surgeon, Dr. Christiaan Barnard, onto the cover of Life magazine and to overnight celebrity status.

This highly publicized event was followed by a brief surge in the procedure around the world, but overall, heart transplants had a rocky start. Most patients died shortly after the surgery, mainly due to organ rejection. Back then, immunosuppressive drugs, which can counteract rejection, were still in their infancy. Many hospitals stopped doing heart transplants in the 1970s.

That changed with the discovery of a highly effective immunosuppressive agent. Cyclosporine got FDA approval in 1983 and altered the world of organ transplants.

It was shortly thereafter when Emory University Hospital decided to launch a heart transplant program, but none of the senior surgeons wanted to do it. Even with the new drug, it was a risky surgery, and mortality was still high.

Its an all-or-nothing operation, Murphy says, as he sits down in his small office overlooking the grayish hospital compound. Hes wearing light blue scrubs from an early morning surgery. At 70, he still has boyish looks, with a lean build and an air of laid-back confidence. If you have a number of bad outcomes initially, it can be detrimental to your career as a surgeon, he says.

But Murphy didnt really have a choice. He remembers that during a meeting of Emorys cardiac surgeons in 1984, he was paged to check on a patient. When he returned, the physicians congratulated him on being appointed the head of the new heart transplant program. He was the youngest in the group and had been recruited from Harvards Massachusetts General Hospital just three years before.

Yeah, thats how I became Emorys first transplant surgeon, says Murphy.

He flew to California to shadow his colleagues at Stanford University Hospital, where most heart transplants were performed at the time. Back home at Emory, he put together a team and rigorously rehearsed the operation. The first transplant patient arrived in April 1985. The surgery was successful, as was the second operation less than a month later.

Around the same time, Harry Wuest wound up in a hospital in Orlando. He needed a transplant, but none of the medical centers in Florida offered the procedure. One of his doctors recommended Emory, and Wuest agreed. I knew I was dying. I could feel it. He was flown to Atlanta by air ambulance and spent several weeks in Emorys cardiac care unit until the evening of May 23, when Murphy walked into his room and said, Weve got a heart.

I could finally breathe again

The heart, as the patient later learned, came from a 19-year-old sophomore at Georgia Tech who had been killed in a car crash.

Organ transplants are a meticulously choreographed endeavor, where timing, coordination and logistics are key. While Murphy and his eight-member team were preparing for the surgery, Wuest was getting ready to say farewell to his family his wife and three teenage sons, and to thank the staff in the cardiac ward.

I was afraid, he recalls, especially of the anesthesia. It scared the heck out of me. He pauses during the reminiscence, choking briefly. I didnt know if I was going to wake up again.

The surgery took six hours. Transplants usually happen at night because the procurement team, the surgeons who retrieve different organs from the donor, only start working when regularly scheduled patients are out of the operating room.

Despite the cultural mystique surrounding the heart as the seat of life, Murphy says that during a transplant surgery, its not like the big spirit comes down to the operating room. Its very technical. As the team follows a precise routine, emotions are kept outside the door. We dont have time for that. Emotions come later.

Waking up from the anesthesia, Wuests first coherent memory was of Murphy entering the room and saying to a nurse, Lets turn on the TV, so Harry can watch some sports.

Wuest spent the next nine days in the ICU, and three more weeks in the hospital ward. In the beginning, he could barely stand up or walk, because he had been bedridden weeks before the surgery and had lost a lot of muscle. But his strength came back quickly. I could finally breathe again, he says. Before the surgery, he felt like he was sucking in air through a tiny straw. I cannot tell you what an amazing feeling that was to suddenly breathe so easily.

Joane Goodroe was the head nurse at Emorys cardiovascular post-op floor back then. When she first met Wuest before the surgery, she recalls him lying in bed and being very, very sick. When she and the other nurses finally saw him stand up and move around, he was a whole different person.

In the early days of Emorys heart transplant program, physicians, nurses and patients were a particularly close-knit group, remembers Goodroe, whos been a nurse for 42 years and now runs a health care consulting firm. There were a lot of firsts for all of us, and we all learned from each other, she said.

Wuest developed friendships with four other early transplant patients at Emory, and he has outlived them all.

When he left the hospital, equipped with a new heart and a fresh hunger for life, Wuest made some radical changes. He decided not to return to Florida but stay in Atlanta. Thats where he felt he got the best care, and where he had found a personal support network. And he got a divorce. Four months after the operation, he went back to working full-time: first in temporary jobs and eventually for a property management company.

After having been sick for 12 years, I was just so excited to be able to work for eight hours a day, he recalls. That was a big, big deal for me.

At 50, he went back to school to get his CPA license. He also found new love.

Martha was a head nurse in the open-heart unit and later ran the cardiac registry at Saint Josephs Hospital. Thats where Wuest received his follow-up care and where they met in 1987. Wuest says for him it was love at first sight, but it took another five years until she finally agreed to go out with him. Six months later, they were married.

Harry Wuest and his wife, Martha. She was a head nurse in the open-heart unit and later ran the cardiac registry at Saint Josephs Hospital. Thats where Wuest received his follow-up care and where they met in 1987. Wuest says for him it was love at first sight, but it took another five years until she finally agreed to go out with him. Six months later, they were married.

Having worked in the transplant office, I saw the good and the bad, Martha Wuest says. A petite woman with short, perfectly groomed silver hair, she sits up very straight on the couch, her small hands folded in her lap. Not every transplant patient did as well as Harry. And I had a lot of fear in the beginning. Now he may well outlive her, she says with a smile and a wink.

Wuests surgeon, meanwhile, went on to fight his own battles. Two and a half years into the program, Murphy was still the only transplant surgeon at Emory and on call to operate whenever a heart became available. Frustrated and exhausted, he quit his position at Emory and signed up with Saint Josephs (which at the time was not part of the Emory system) and started a heart transplant program there.

At St. Josephs, Murphy continued transplanting hearts until 2005. In total, he did more than 200 such surgeries.

Being a heart transplant surgeon is a grueling profession, he says, and very much a younger surgeons subspecialty.

He then shifted his focus and became a pioneer in robotically assisted heart surgery. He has done more than 3,000 operations with the robot, mostly mitral valve repairs and replacements more than any other cardiac surgeon in the world.

Heart transplants "remain the gold standard"

Since Murphy sewed a new heart into Wuest 35 years ago, there has been major progress in the field of heart transplants, but it has been uneven.

There is improved medication to prevent rejection of the donor heart, as well as new methods of preserving and transporting donor hearts.

Yet patients requiring late-stage heart failure therapy, including transplantation, still exceed the number of donor hearts available. In 2019, 3,551 hearts were transplanted in the United States, according to the national Organ Procurement and Transplantation Network. But 700,000 people suffer from advanced heart failure, says the American Heart Association.

New technologies and continued research are providing hope to many of these patients. There has been significant progress in the development of partial artificial hearts, known as Left Ventricular Assist Devices, or LVADs. They can be used as bridge devices, to keep patients alive until donor hearts are available, or as destination therapy, maintaining patients for the remainder of their lives.

Also, total artificial hearts have come a long way since the first artificial pump was implanted in a patient in 1969. The technology is promising, says Dr. Mani Daneshmand, the director of Emorys Heart & Lung Transplantation Program. But its not perfect.

Long-term research continues into xenotransplantation, which involves transplanting animal cells, tissues and organs into human recipients.

Regenerative stem cell therapy is an experimental concept where stem cell injections stimulate the heart to replace the rigid scar tissue with tissue that resumes contraction, allowing for the damaged heart to heal itself after a heart attack or other cardiac disease. Certain stem cell therapies have shown to reverse the damage to the heart by 30 to 50 percent, says Dr. Joshua Hare, a heart transplant surgeon and the director of the Interdisciplinary Stem Cell Institute at the University of Miamis Miller School of Medicine.

All of these ideas have potential, says Daneshmand. But none of them are ready to replace a human donor heart. A heart transplant remains the gold standard, because you cant accommodate the same success with a machine right now, he says.

Efforts around expanding the donor pool are really the best way to address this problem, while we wait for technology to catch up, he adds.

Besides Emory, other health care systems in Georgia that currently have a heart transplant program are Piedmont Healthcare, Childrens Healthcare of Atlanta and Augusta University Health.

Organ rejection remains a major issue, and long-term survival rates have not improved dramatically over the past 35 years. The 10-year survival is currently around 55 percent of patients, which makes long-term survivors like Harry Wuest rare in the world of heart transplants.

The United Network of Organ Sharing, or UNOS, which allocates donor hearts in the United States, doesnt have comprehensive data prior to 1987. An informal survey of the 20 highest-volume hospitals for heart transplants in the 1980s found only a scattering of long-term survivors.

In for the long haul

Being one of the longest-living heart transplant recipients is something that Wuest sees as a responsibility to other transplant patients, but also to the donors family, which hes never met. If you as a transplant recipient reject that heart, thats like a second loss for that family.

Part of this responsibility is living a full and active life. Both he and Martha have three children from their previous marriages and combined they have 15 grandchildren. Most of their families live in Florida, so they travel back and forth frequently. Wuest still works as a CPA during tax season, and he does advocacy for the Georgia Transplant Foundation. In addition to golf, he enjoys lifting weights and riding his bike.

Hes had some health scares over the years. In 2013, he was diagnosed with stage 1 kidney cancer, which is in remission. Also, he crossed paths with his former surgeon, and not just socially. In 2014, Murphy replaced a damaged tricuspid valve in Wuests new heart. That operation went well, too.

Murphy says there are several reasons why Wuest has survived so long. Obviously, his new heart was a very good match. But a patient can have the best heart and the best care and the best medicines and still die a few months or years after the transplantation, the surgeon says. Attitude plays a key role.

Wuest was psychologically stable and never suffered from depression or anxiety, Murphy says. Hes a numbers guy. He knew the transplant was his only chance, and he was set to pursue it.

Wuest attributes his longevity to a good strong heart from his donor; good genetics; great doctors and nurses; and a life that he loves. Im just happy to be here, he says.

Quoting his former surgeon and friend, he adds: Doug always said, Having a transplant is like running a marathon. And Im in for the long haul.

Original post:

34 years with a new heart and counting - MDJOnline.com

Lineage Cell Therapeutics to Present New Data From OpRegen and Vision Restoration Programs at the Association for Research in Vision and Ophthalmology…

CARLSBAD, Calif.--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that updated results from a Phase I/IIa study of its lead product candidate, OpRegen, a retinal pigment epithelium (RPE) cell transplant therapy currently in development for the treatment of dry age-related macular degeneration (dry AMD), have been accepted for presentation at the 2020 Association for Research in Vision and Ophthalmology (ARVO) Meeting, which will be held May 3rd through May 7th, 2020 at the Baltimore Convention Center in Baltimore, MD. The abstract presentation, entitled, Phase I/IIa Clinical Trial of Human Embryonic Stem Cell (hESC)-Derived Retinal Pigmented Epithelium (RPE, OpRegen) Transplantation in Advanced Dry Form Age-Related Macular Degeneration (AMD): Interim Results, will be presented as part of the Gene Therapy and Stem cells Session on May 3rd, 2020 from 3:00PM to 4:45PM EDT by Christopher D. Riemann, M.D., Vitreoretinal Surgeon and Fellowship Director, Cincinnati Eye Institute and University of Cincinnati School of Medicine; Clinical Governance Board, Cincinnati Eye Institute (presentation number 865). The presentation will provide updated data from patient cohorts 1 through 4 of the clinical study and will include data on the first patients dosed with both a new subretinal delivery system as well as with a new Thaw-and-Inject (TAI) formulation of OpRegen.

We continue to be encouraged by positive data with OpRegen for the treatment of dry AMD, stated Brian M. Culley, CEO of Lineage. The five patients treated as part of cohort 4, which more closely match our intended patient population, have all demonstrated an increase in the number of letters they can read on an Early Treatment Diabetic Retinopathy Scale (ETDRS), having gained between 10 25 letters. Importantly, the first patient treated using both a new subretinal delivery system and our TAI formulation of OpRegen demonstrated notable improvements in vision, having gained 25 readable letters (or 5 lines) 6 months following administration of OpRegen RPE cells, as assessed by the ETDRS. This represents an improvement in visual acuity from a baseline of 20/250 to 20/100 in the treated eye. These visual acuity measurements are meaningful and can translate into quality of life enhancements to things like reading, driving, or avoiding accidents. With the opening of two leading ophthalmology research centers as clinical sites for our study, we are focused on rapid enrollment so that our clinical update at ARVO can be as mature and informative as possible. Our objective is to combine the best cells, the best production process and the best delivery system, which we believe will position us as the front-runner in the race to address the unmet opportunity in the potential billion-dollar dry AMD market.

In addition, Lineage will present new preclinical results from its Vision Restoration Program, a proprietary program based on the ability to generate 3-dimensional human retinal tissue derived from pluripotent cells. Lineages 3-dimensional retinal tissue technology may address the unmet need of implementing a retinal tissue restoration strategy to address a wide range of severe retinal degenerative conditions including retinitis pigmentosa and advanced forms of AMD. In 2017 and 2019, the Small Business Innovation Research program of the National Institutes of Health awarded Lineage grants of close to $2.3 million to further develop this innovative, next generation vision restoration program.

- The poster presentation, entitled, Transplantation of organoid-derived human retinal tissue in to the subretinal space of CrxRdy/+ cats), will be presented as part of the Animal models for visual disease and restoration Session on May 4th, 2020 4:00PM to 5:45PM EDT in Session Number 291 by Igor Nasonkin, Ph.D., Principal Investigator, Director of Research & Development at Lineage (Poster board Number: 2253 - B0162).

- The poster presentation, entitled, Intraocular biocompatibility of Hystem hydrogel for delivery of pharmaceutical agents and cells, will be presented as part of the Stem cells and organoids: Technical advances Session on May 5th, 2020 between 8:45AM to 10:30AM EDT in Session Number 332 by our collaborator Randolph D. Glickman, Ph.D., Professor of Ophthalmology, UT Health San Antonio (Poster board Number: # A0247).

About Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineages programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally-differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed either to replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineages clinical programs are in markets with billion dollar opportunities and include (i) OpRegen, a retinal pigment epithelium transplant therapy in Phase I/IIa development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase I/IIa development for the treatment of acute spinal cord injuries; and (iii) VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells currently in Phase I development for the treatment of non-small cell lung cancer. Lineage is also evaluating potential partnership opportunities for Renevia, a facial aesthetics product that was recently granted a Conformit Europenne (CE) Mark. For more information, please visit http://www.lineagecell.com or follow the Company on Twitter @LineageCell.

Forward-Looking Statements

Lineage cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as believe, may, will, estimate, continue, anticipate, design, intend, expect, could, plan, potential, predict, seek, should, would, contemplate, project, target, tend to, or the negative version of these words and similar expressions. Such statements include, but are not limited to, statements relating to the potential applications in Lineages Vision Restoration Program. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Lineages actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including risks and uncertainties inherent in Lineages business and other risks in Lineages filings with the Securities and Exchange Commission (the SEC). Lineages forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. Further information regarding these and other risks is included under the heading Risk Factors in Lineages periodic reports with the SEC, including Lineages Annual Report on Form 10-K filed with the SEC on March 14, 2019 and its other reports, which are available from the SECs website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Lineage undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Here is the original post:

Lineage Cell Therapeutics to Present New Data From OpRegen and Vision Restoration Programs at the Association for Research in Vision and Ophthalmology...